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Abstract
Though the management of diabetes is widely documented in scientific literature, little is
published about how hypoglycemia is managed by family physicians. The objective of this
study was to create a measurement for family physician clinical inertia in managing
hypoglycemia, and to determine family physicians’ characteristics associated with clinical
inertia. The design was a secondary analysis of the data provided by 162 family physicians
from the Canadian InHypo-DM Study. The outcome for this thesis was a score for
physician clinical inertia. The methods applied were exploratory factor analysis, bivariate
analysis and multiple linear regression. Results showed no statistically significant
differences in clinical inertia score for any of the independent variables. This study
provides evidence that clinical inertia in management of hypoglycemia is not associated
with family physicians’ characteristics. Further testing this score will provide more
information on aspects of clinical inertia and its role in the management of hypoglycemia.

Keywords
Hypoglycemia Management in Family Physicians, Clinical Inertia in Hypoglycemia
Management, Clinical Inertia in Family Physicians, Diabetes in Primary Care,
Hypoglycemia, Clinical Inertia, InHypo-DM, Exploratory Factor Analysis.

ii

Co-Authorship Statement
This thesis and the associated secondary analysis were developed, planned and performed
by the author. Data for the In-Hypo-DM Study were collected by researchers in Dr.
Stewart Harris’ (Principal Investigator) team at Western University. The exploratory factor
analysis, multiple regression and correlation analysis were completed by the author and
reviewed with Drs. Bridget Ryan and Stewart Harris. The thesis was written solely by the
author, with editorial advice from Drs. Bridget Ryan and Stewart Harris.

iii

Acknowledgments
I must recognize and thank the wonderful people who have helped to make this thesis
possible:
Dr. Stewart Harris for his proficient advice, support and guidance along the way.
Dr. Bridget Ryan for her immense patience, graceful guidance and support during the entire
process.
Dr. Paul Tremblay for statistical advice.
My father and mother, Waldir and Beatrix Martignoni, for inspiring me to reach higher
grounds.
Most importantly, I wish to thank my husband, Rafael, for his encouragement, patience,
and never-ending support, and our children, Thomas, Louise, Samuel, Arthur and Daniel
for their love and patience.

iv

Table of Contents
Abstract .................................................................................................................................i
Co-Authorship Statement ................................................................................................... ii
Acknowledgments ............................................................................................................. iii
List of Tables ................................................................................................................... viii
List of Figures ...................................................................................................................... x
List of Appendices ..............................................................................................................xi
List of Abbreviations ..........................................................................................................xi
Preface ..............................................................................................................................xiv
Chapter 1 ............................................................................................................................. 1
1 Overview......................................................................................................................... 1
Chapter 2 ............................................................................................................................. 2
2 Diabetes, Hypoglycemia and Clinical Inertia ................................................................. 2
2.1 Diabetes ................................................................................................................... 2
Diabetes Prevalence ..................................................................................... 2
2.2 Hypoglycemia .......................................................................................................... 3
Definition ..................................................................................................... 3
Relevance..................................................................................................... 5
Risk Factors for Hypoglycemia ................................................................... 6
Glycemic Goals ........................................................................................... 8
Hypoglycemia-inducing pharmacologic agents .......................................... 9
Treatment of Hypoglycemia ...................................................................... 10
Hypoglycemia Management in Primary Healthcare ................................. 11
The Care Gap ............................................................................................. 12

v

2.3 Clinical Inertia ....................................................................................................... 13
Overview ................................................................................................... 13
Definition ................................................................................................... 14
Clinical Inertia in Primary Care ................................................................ 15
Theoretic Models of Clinical Inertia ......................................................... 17
Barriers to Behavior Change ..................................................................... 18
The Challenge ............................................................................................ 19
Chapter 3 ........................................................................................................................... 20
3 Methodology ................................................................................................................. 20
3.1 Study Objectives .................................................................................................... 20
3.2 Study Design ......................................................................................................... 20
3.3 Data Source: The InHypo-DM Study .................................................................... 20
InHypo-DM Study Overview .................................................................... 20
InHypo-DM: Methodology ....................................................................... 21
InHypo-DM: Theoretical Domains Framework Tool ............................... 21
InHypo-DM: Questionnaires ..................................................................... 21
InHypo-DM: HCP Sampling ..................................................................... 22
InHypo-DM: HCP Respondents – Descriptive Results............................. 23
3.4 Sample ................................................................................................................... 24
3.5 Variables ................................................................................................................ 24
Dependent Variable ................................................................................... 24
Independent Variables ............................................................................... 26
3.6 Descriptive Analysis .............................................................................................. 27
3.7 Exploratory Factor Analysis .................................................................................. 27
Adequacy of Sample .................................................................................. 28

vi

Data Verification ....................................................................................... 28
Extraction and Rotation Methods .............................................................. 29
Factor Retention ........................................................................................ 29
3.8 Clinical Inertia Score ............................................................................................. 30
Factor Score ............................................................................................... 30
3.9 Examining the Relationship between the Clinical Inertia Score and Physician
Characteristics ....................................................................................................... 31
Bivariate Analysis ..................................................................................... 31
Multiple Linear Regression ....................................................................... 31
Chapter 4 ........................................................................................................................... 33
4 Results........................................................................................................................... 33
4.1 Family Physician – Descriptive Results ................................................................ 33
4.2 Exploratory Factor Analysis .................................................................................. 36
Adequacy of Sample .................................................................................. 36
Data Verification ....................................................................................... 37
4.3 Factor Analysis – Round 1 .................................................................................... 38
EFA-1 Extraction and Rotation Methods .................................................. 38
Retaining Factors ....................................................................................... 41
4.4 Factor Analysis – Round 2 .................................................................................... 42
EFA -2 Extraction and Rotation Methods ................................................. 42
Factors in EFA - 2 ..................................................................................... 45
4.5 Factor Analysis – Round 3 .................................................................................... 45
One Factor Solution – 13 item scale.......................................................... 46
4.6 Factor Analysis – Round 4 .................................................................................... 47
One Factor Solution – 12 item scale.......................................................... 47

vii

4.7 Clinical Inertia Score ............................................................................................. 49
4.8 The Relationship between the Clinical Inertia Score and Family Physician
Characteristics ....................................................................................................... 50
Bivariate Analysis ..................................................................................... 51
Multiple Linear Regression ....................................................................... 53
Chapter 5 ........................................................................................................................... 58
5 Discussion ..................................................................................................................... 58
5.1 Summary of Findings ............................................................................................ 58
5.2 Implication of Findings ......................................................................................... 58
5.3 Strengths and Limitations ...................................................................................... 61
5.4 Conclusion ............................................................................................................. 62
References ......................................................................................................................... 64
Appendices ........................................................................................................................ 71

viii

List of Tables
Table 2-a: Symptoms of Hypoglycemia ................................................................................. 4
Table 2-b: Severity of Hypoglycemia .................................................................................... 5
Table 2-c: Classification of Hypoglycemia ............................................................................ 5
Table 2-d: Risk factors for Severe Hypoglycemia ................................................................. 7
Table 2-e: Barriers to Behavior Change ............................................................................... 18
Table 3-a: Comparison of Other Health Care Provider and Physician Characteristics ........ 24
Table 3-b: Potential Items for the Clinical Inertia Scale ...................................................... 25
Table 4-a: Family Physician Respondent Characteristics – Continuous Variables.............. 34
Table 4-b: Family Physician Respondent Characteristics – Categorical Variables ............. 36
Table 4-c: Correlation Matrix ............................................................................................... 37
Table 4-d: Sample Adequacy tests ....................................................................................... 37
Table 4-e: Normality Tests .................................................................................................. 38
Table 4-f: Pattern and Structure Matrix for EFA-1 with Oblimin Rotation ......................... 40
Table 4-g: Total Variance Explained EFA-1 ........................................................................ 40
Table 4-h: Factor correlation Matrix EFA – 1..................................................................... 41
Table 4-i: Pattern and Structure Matrix for EFA-2 with Oblimin Rotation ......................... 43
Table 4-j: Total variance Explained EFA-2 ......................................................................... 43
Table 4-k: Factor Correlation Matrix EFA-2 ....................................................................... 44
Table 4-l: Cronbach`s Alpha EFA -2 ................................................................................... 44

ix

Table 4-m: Loading values (Pattern coefficients) for variables in EFA-2 Factor #1 ........... 45
Table 4-n: Loading values (Pattern coefficients) for variables in EFA-2 Factor #2 ............ 45
Table 4-o: Factor Matrix EFA – 3 (One-factor, 13-item)..................................................... 46
Table 4-p: Total Variance Explained EFA -3 (One-factor, 13-item) ................................... 47
Table 4-q: Factor Matrix EFA – 4 (One-factor, 12-item)..................................................... 48
Table 4-r: Total Variance Explained EFA – 4 (One-factor, 12-item) .................................. 49
Table 4-s: Descriptive Results .............................................................................................. 50
Table 4-t: Correlation for Continuous Variables and Clinical Inertia Score ........................ 51
Table 4-u: Clinical Inertia Scores and T-test Results for Dichotomous variables ............... 52
Table 4-v: Clinical Inertia Score for Province Categories ................................................... 52
Table 4-w: Clinical Inertia Score for Practice Type Categories ........................................... 53
Table 4-x: ANOVA for Province Variable........................................................................... 53
Table 4-y: ANOVA for Practice Type Variable ................................................................... 53
Table 4-z: Correlation in MLR -2......................................................................................... 55
Table 4-aa: Coefficients MLR - 2......................................................................................... 57

x

List of Figures
Figure 2-a: Clinical Inertia in DM Care ............................................................................... 17
Figure 3-a: Consort Diagram for the In-HypoDM Study, HCP sampling ........................... 23
Figure 4-a: Distribution of FP Respondents across Canada (%) .......................................... 35
Figure 4-b: Scree plot EFA-1 ............................................................................................... 41
Figure 4-c: Scree plot EFA-2 ............................................................................................... 44
Figure 4-d: Illustration of the Iterative Process for EFA . ................................................... 47
Figure 4-f: Outcome normality assessment .......................................................................... 50
Figure 4-g: P-P Plot MLR - 2 ............................................................................................... 55
Figure 4-h: Scatterplot MLR -2 ............................................................................................ 56

xi

List of Appendices
Appendix A: 2018 CDA Clinical Practice Guideline for Hypoglycemia………...………..71
Appendix B: InHypo-DM HCP Questionnaire………………………………………….... 73

List of Abbreviations
A1C - Glycated Hemoglobin
AB - Alberta
ACCORD – Action to Control Cardiovascular Risk in Diabetes
ADA – American Diabetes Association
ANOVA – Analysis of Variance
BC – British Columbia
CDA – Canadian Diabetes Association
CDE – Certified Diabetes Educator
CPG – Clinical Practice guidelines
DM – Diabetes Mellitus
DOVES – Diabetes Outcomes in Veterans Study
DPP-4 – Dipeptidyl Peptidase-4
EFA – Exploratory Factor Analysis
FP – Family Physician
GLP-1 - Glucagon-like peptide-1
HCP – Healthcare Professionals

xii

IDF – International Diabetes Federation
InHypo-DM – Understanding the Impact of Hypoglycemia on Diabetes Management: A
Survey of Perspectives and Practices
IV – Independent Variable
KMO – Kaiser Meyer Olkin
MB - Manitoba
MLR - Multiple Linear Regression
NB – New Brunswick
NL - Newfoundland
NS – Nova Scotia
ON - Ontario
PAF – Principal Axis Factor
PCP – Primary Care Physicians
PEI – Prince Edward Island
PTM – Professional Targeted Marketing
QU - Quebec
SGLT-2 - Sodium-dependent Glucose Co-Transporter-2
SK - Saskatchewan
SO – Significant Others
SPSS – Statistical Package for the Social Sciences

xiii

T1DM – Type 1 Diabetes
T2DM – Type 2 Diabetes
TDF – Theoretical Domain Framework
UKPDS – United Kingdom Prospective Diabetes Study

xiv

Preface
“Confucius, Buddha, Jesus and Muhammad would have been bewildered if you told them
that in order to understand the human mind and cure its illnesses
you must first study statistics.”
The Discovery of Ignorance, Sapiens - A Brief History of Humankind
Yuval N. Harari, 2014

“Neither evidence nor clinical judgment alone is sufficient. Evidence without judgment can
be applied by a technician. Judgment without evidence can be applied by a friend. But the
integration of evidence and judgment is what the healthcare provider does in order to
dispense the best clinical care.”
Hertzel Gerstein, 2012

1

Chapter 1
Overview
Medical knowledge advances at a fast pace, however some issues remain a perplexing
challenge. Even health problems that are old subjects to medical research and are quite
familiar to the medical community, such as diabetes, present intriguing limitations in
everyday clinical practice.
This thesis explores the factors that may contribute to the relationship between management
of hypoglycemia and physician clinical inertia. The starting point for this study was
provided by a recent Canadian nation-wide study on hypoglycemia in diabetes. Data from
family physician respondents who participated in that study were analyzed for this study. In
this first chapter, a brief overview of the steps taken to explore this relationship is laid out.
Chapter two reviews the literature on: diabetes and its relevance in primary care medicine;
hypoglycemia management and recent updates; and clinical inertia. This chapter provides
preliminary concepts and establishes the current facts, guidelines and definitions for these
topics.
The next section, chapter three, describes the objectives and methodologic approaches of
both the original InHypo-DM study and the subsequent secondary analysis conducted for
the purpose of addressing the objectives of this thesis. The steps taken in the analysis of the
original InHypo-DM study Healthcare Provider data set are explained. The sequence of
tests and procedures applied to achieve the study objectives is presented.
The results for the analysis conducted are presented in chapter four.
Chapter five reflects upon the findings of this study as to where they differ from the
existing knowledge, where they confirm the current knowledge, and where those findings
are novel and add to the existing knowledge of clinical inertia in hypoglycemia
management in primary care. Recommendations for future research are presented in this
concluding section.
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Chapter 2
Diabetes, Hypoglycemia and Clinical Inertia
2.1 Diabetes
Diabetes and its related problems are frequent reasons for patient-physician encounters in
primary care worldwide. One of the issues that requires special attention from family
physicians is the risk and occurrence of hypoglycemia in their patients with diabetes on
insulin and/or secretagogues. The ability to appropriately identify and manage this
medication-related adverse event is a central competence of diabetes care. Guidelines
provide evidence-based recommendations to the fundamentals of diabetes management,
and the exemplar physician is capable of individualizing treatment to best achieve patient`s
target and well-being accordingly. Literature on family physician’s awareness, actions and
attitudes towards hypoglycemia and appropriate treatment and intervention in primary care
is substantially limited.

Diabetes Prevalence
"Diabetes is one of the largest health emergencies of the 21st century" concluded the latest
report of the International Diabetes Federation (IDF).1 It is estimated that Diabetes Mellitus
(DM) affected 415 million adults ages 20 to 79 in 2015 worldwide and another 318 million
persons have impaired glucose intolerance and are at a higher risk of developing type 2
diabetes (T2DM). Diabetes, particularly T2DM, is one of the most common chronic
diseases in nearly all countries, and continues to increase in numbers and significance,
particularly in developing nations. The Brazilian Health Ministry detected in 2018 that the
incidence rate of DM increased by 61.8% in the last 10 years, rising from 5.5% of the
population in 2006 to 8.9% in 2016.2
Following the global trend, Canada’s rates of DM are also rising. It is estimated that an
increase of 44% will be observed between 2015 to 2025 in the prevalence of DM among
Canadians. Diabetes is the leading cause of blindness, end stage renal disease and nontraumatic amputation in Canadian adults.3
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Possible reasons for this DM epidemic include economic development and urbanization
that lead to rapid cultural and social changes in traditional lifestyles characterized by
reduced physical activity, ageing populations, increased urbanization, industrialized diet
with increased sugar consumption and low fruit and vegetable intake, and consequently,
increased obesity.1
Globally, one in every 11 adults (8.8%) has DM and half of these are unaware of it1. In
high-income countries, approximately 87 to 91% of all people with diabetes are estimated
to have T2DM, 7% to 12% are estimated to have type 1 diabetes (T1DM) and 1% to 3% to
have other types of DM1.

2.2 Hypoglycemia
Definition
Hypoglycemia is defined biochemically as blood glucose concentration less than 4.0
mmol/L, or 70mg/dL.4 The Canadian Diabetes Association (CDA), now known as Diabetes
Canada, recently published a more sophisticated definition in their Clinical Practice
Guidelines (CPG),5 where hypoglycemia is defined by three components:
•

Development of autonomic or neuroglycopenic symptoms (Table 2-a);

•

Low plasma glucose level (<4.0 mmol/L for patients treated with insulin or insulin
secretagogue); and

•

Symptoms responding to the administration of carbohydrate
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Table 2-a: Symptoms of Hypoglycemia
Neurogenic
(autonomic)

Neuroglycopenic

Trembling

Difﬁculty
concentrating

Palpitations
Sweating
Anxiety
Hunger
Nausea
Tingling

Confusion
Weakness
Drowsiness
Vision changes
Difﬁculty speaking
Headache Dizziness

Ref.: Yale, JF et al. Diabetes Canada. 2018 Clinical Practice Guidelines, Hypoglycemia. Can J Diabetes. 2018. Cryer, PE
et al. Insulin Therapy and Hypoglycemia in Type 2 Diabetes Mellitus. Insulin 2007

Hypoglycemia is clinically classified by the severity of symptoms in the hypoglycemic
event and by the individual's ability to self-treat. When blood glucose levels drop below
3.3 mmol/L, most patients experience unpleasant neuroglycopenic or autonomic
progressive symptoms (Table 2-a). The first is the result of brain deprivation of glucose,
leading to confusion, sensation of warmth, weakness or fatigue, severe cognitive failure,
seizure and ultimately, if not reversed, coma. The latter are the result of the perception of
physiologic changes caused by the autonomic nervous system's response to hypoglycemia,
manifested as tremulousness, palpitations, anxiety, sweating, hunger, paresthesia. This
state of physiological discomfort forces the individual to seek an action that normally
prevents or rapidly corrects clinical hypoglycemia.6 Most episodes of lower blood glucose
are associated with excessive use of medication, dietary mistakes, and physical exercise7;
decreased glucose absorption in gastroenteritis and vomiting; or decreased glucose
production in liver disease and alcohol intoxication.8
In mild to moderate events, the patient can manage hypoglycemia him/her self by
identifying the characteristic symptoms and ingesting enough carbohydrates to elevate
blood glucose. Severe hypoglycemia happens when the patient is unable to identify the
characteristic symptoms and/or is incapable of resolving the problem, needing assistance
from others to recover.9 The severity of hypoglycemia is defined by clinical manifestations
and consequences listed in Table 2-b.5
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Table 2-b: Severity of Hypoglycemia
Mild: Autonomic symptoms are present. The individual is able to self-treat.
Moderate: Autonomic and neuroglycopenic symptoms are present.
The individual is able to self-treat.
Severe: Unconsciousness may occur. Plasma glucose is typically <2.8 mmol/L. The Individual
requires assistance of another person to treat.
Ref.: Yale, JF et al. Diabetes Canada. 2018 Clinical Practice Guidelines, Hypoglycemia. Can J Diabetes. 2018.

The American Diabetes Association (ADA) recently revised their definitions for
hypoglycemia10.
Table 2-c presents elements that characterize clinical hypoglycemia.

Table 2-c: Classification of Hypoglycemia
Level
Glucose alert value
(level 1)

Glycemic Criteria

Description

70 mg/dL (3.9
mmol/L)

Clinically significant
hypoglycemia
(level 2)
Severe hypoglycemia
(level 3)

54 mg/dL (3.0
mmol/L)

Sufficiently low for treatment with
fast-acting carbohydrate and dose
adjustment of glucose-lowering
therapy
Sufficiently low to indicate serious,
clinically important hypoglycemia

No specific glucose
threshold

Hypoglycemia associated with
severe cognitive impairment
requiring external assistance for
recovery

Ref.: Diabetes Care - Standards of Care, Hypoglycemia, 2019 Suppl.1 S67 American Diabetes Association

Relevance
Hypoglycemia is commonly associated with people with T1DM, but is also seen in T2DM
patients managed by insulin and/or, sulfonylureas.5 Ratzki-Leewing et al11 analyzed the
results of the largest real-world investigation of hypoglycemia epidemiology in Canada and
affirmed that the incidence of hypoglycemia among adults with DM taking insulin and/or
insulin secretagogues is higher than previously thought. In their paper, the authors stated
that, while 83.0% of people with T1DM reported having experienced at least one
hypoglycemic event with an overall annualized hypoglycemia rate of 58.1 events per
person-year, 62.0% of T2DM individuals experienced at least one hypoglycemia event at a
rate of 30.4 events per person-year.
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Hypoglycemia is less common in the early stages of T2DM because the glucose plasma
counter-regulatory mechanisms tend to be preserved in these patients. However, if patient
management at this stage of diabetes includes oral hypoglycemic agents, such as
secretagogues, or those on an insulin regimen, hypoglycemia can occur and therefore can
be an important complicating factor in efforts to achieve tighter glycemic control.
The United Kingdom Prospective Diabetes Study (UKPDS)12, was a landmark study in the
treatment of T2DM that has influenced standards of care and treatment guidelines
throughout the world. That study found that severe hypoglycemia occurred in 11% of
subjects on aggressive therapy over a 6-year follow-up period. The Diabetes Outcomes in
Veterans Study (DOVES)13, was another important study which identified clinical and
behavioral factors associated with glucose variability in T2DM. It reported 5.5% of subjects
experienced severe hypoglycemia over the 8-week observation period7. One author has
boldly stated that hypoglycemic events are nearly inevitable in patients if tight glycemic
control is to be achieved.15
Life-threatening, severe hypoglycemia in T2DM patients was believed to be a relatively
infrequent event7, but a recent national epidemiologic study in Canada has challenged that
idea. Ratzki-Leewing et al found that, in the InHypo-DM questionnaire answered by
patients with diabetes reporting any type of hypoglycemic event, “the incidence rate of
severe hypoglycemia was approximately 37% higher in people with T2DM” than that found
among those respondents who were T1DM.11 page 6

Risk Factors for Hypoglycemia
The odds of experiencing hypoglycemia in people with T2DM have been measured by
Reichert et al14 and the authors found that they were highest among younger adults, those
with poor glycemic control, those who took multiple daily injections of insulin, and those
who lead busy lives (working full time and/or shift work).
Type 2 DM patients are at a higher risk of experiencing severe hypoglycemia when the
following factors are present: advancing age, severe cognitive impairment, poor health
literacy, food insecurity, hypoglycemia unawareness, prolonged duration of insulin therapy,
renal impairment and neuropathy.4 Another large landmark study for T2DM patients with
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elevated risk for cardiovascular disease, the Action to Control Cardiovascular Risk in
Diabetes trial (ACCORD)16, identified additional risk factors for that population including:
female gender, African-American race and less than high-school education.17
A compilation of major risk factors cited in Diabetes Canada’s Clinical Practice Guideline
(CPG) for severe hypoglycemia is presented in Table 2-d.
Table 2-d: Risk factors for Severe Hypoglycemia
Diabetic Patients presenting with these conditions are
at risk for severe hypoglycemic events
Prior episode of severe hypoglycemia
Current low glycated hemoglobin (<6.0%)
Hypoglycemia unawareness
Long duration of insulin therapy
Autonomic neuropathy
Low economic status
Food insecurity
Low health literacy
Cognitive impairment
Adolescence
Long duration of Insulin therapy
Presence of complications (renal impairment or
neuropathy)
Persons unable to detect and/or treat mild
hypoglycemia on their own
Ref.: Yale, JF et al. Diabetes Canada. 2018 Clinical Practice Guidelines, Hypoglycemia. Can J Diabetes. 2018.

In the early stages of T2DM, when physiologic defenses against hypoglycemia are intact,
the mechanisms for preventing the lowering of blood glucose (down regulation of insulin
secretion in β-cell and increase in α-cell glucagon or epinephrine secretion) support
euglycemic levels. Over the course of the illness, with progressive beta cell decline
hyperglycemia often becomes an issue that patients struggle with. Impairment of
sympathetic neural response occurs in consequence of sustained hyperglycemia. At this
stage many individuals develop a condition where there is an impairment of the ability to
perceive the warning symptoms of hypoglycemia, or even the loss of sympathetic neural
response. This impairment of hypoglycemia awareness is mediated by an "adaptation of
the hormonal counter-regulatory response towards low blood glucose levels"15 page 229 and it
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consists of a reduced ability to perceive the "warning symptoms" due to a lower threshold
of these symptoms. A destructive cycle of hypoglycemia induced by previous
hypoglycemia is a critical predictive risk factor for severe hypoglycemic episodes15. This
poses a challenge for aggressive treatment regimens that put patients at risk for
hypoglycaemia, for example patients on insulin and/or secretagogues.
In the ADA’s recently reviewed guidelines, insulin-treated patients with hypoglycemia
unawareness or an episode of clinically significant hypoglycemia (< 3.0 mmol/L) should be
advised to raise their glycemic targets to strictly avoid hypoglycemia for at least several
weeks to partially reverse hypoglycemia unawareness and reduce risk of future episodes.18
According to Heller, strategies to diminish the risk of hypoglycemia from the provider’s
stand point should be guided by three principles19:
•

Individual targets adjusted for patient’s vulnerability to hypoglycemia;

•

Structured education and training for people with diabetes; and

•

Team care that is alert to potential problems with hypoglycemia.

Glycemic Goals
Evidence-based guidelines compels the primary care physicians (PCP) to set customized
targets for each patient’s blood glucose levels after considering several factors. Intensive
glucose control, lowering glycated hemoglobin (A1C) values to ≤7% in both T1DM and
T2DM, provides strong benefits for prevention of microvascular complications and, if
achieved early in the disease, likely provides a significant macrovascular benefit, especially
as part of a multifactorial treatment approach. More intensive glucose control, A1C ≤6.5%,
may be sought in patients with a shorter duration of diabetes, no evidence of significant
cardiovascular disease and longer life expectancy, as long as this does not result in a
significant increase in hypoglycemic events. An A1C target ≤8.5% may be more
appropriate in T1DM and T2DM with limited life expectancy, higher level of functional
dependency, a history of severe hypoglycemia, advanced comorbidities, and a failure to
achieve established glucose targets despite treatment intensification.20
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According to guidelines, if lifestyle and dietary modifications fail to achieve target A1C
after two to three months of adjustments, it is recommended that antihyperglycemic
pharmacotherapy should be initiated. Unless contraindicated or the patient is intolerant,
metformin should be the initial agent of choice. Additional antihyperglycemic agents
should be selected on the basis of clinically relevant issues and always tailored to each
patient’s individual characteristics and glycemic target, such as: contraindication to drug,
glucose lowering effectiveness, risk of hypoglycemia and effect on body weight. Timely
adjustments to, and/or additions of other antihyperglycemic agents should be made to reach
target A1C within three to six months. In patients with marked hyperglycemia (A1C
≥1.5% above individualized target), antihyperglycemic agents should be initiated along
with lifestyle modifications, and consideration should be given to initiating combination
therapy with two agents, one of which may be insulin.21

Hypoglycemia-inducing pharmacologic agents
Glucose lowering agents used to treat T2DM can contribute to a patient’s risk for
hypoglycemia, with some agents more likely to produce hypoglycemia than others.
Biguanides (e.g. metformin) lower blood glucose by mechanisms other than increasing
blood level of insulin, working in a glucose-dependent manner. Metformin, for example,
decreases hepatic glucose production and increases insulin sensitivity. This group of agents
are considered at low-risk for causing hypoglycemia and unlikely to induce hypoglycemia
when used as monotherapy.8 The Diabetes Canada 2018 CPG recommends metformin as a
first-line therapy for individuals without metabolic decompensation. However, if metabolic
decompensation is present, insulin is the choice for initial treatment.3
Secretagogues, a common choice for second-line therapy, stimulate insulin secretion from
pancreatic β-cells in a glucose-independent manner, and thus, are associated with a highrisk of hypoglycemia. Recent studies with practice-changing evidence have proven that in
adults with T2DM with clinically significant cardiovascular disease in whom glycemic
targets are not met, the second antihyperglycemic agent to be added should be one with
demonstrated cardiovascular outcome benefit. Some SGLT-2 inhibitors (i.e. empagliflozin
and canagliflozin) have shown such benefits without increasing risk of hypoglycemia.21
Other antihyperglycemic agents, such as glucagon-like peptide-1 (GLP-1) receptor
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agonists, have also shown benefits for T2DM patients with cardiovascular risk factors and
unmet A1C targets21 (i.e. liraglutide).
Insulin is generally considered as the third-line therapy and the group of agents most likely
to cause hypoglycemia amid the medications in the high-risk category.22 A combination of
oral antihyperglycemic and insulin often effectively control glucose levels. The choice of
insulin and insulin regimen should take into consideration multiple type-specific
advantages and disadvantages and patient’s needs, preferences and context.
Current evidence from a systematic review and meta-analysis by Edridge et al shows that
hypoglycemia is considerably prevalent amongst people with T2DM, particularly for those
on secretagogues or insulin.23

Treatment of Hypoglycemia
Treatment of hypoglycemia can be easily accessed in most settings. Patient education is
essential. Orientation may include discussing with patient a plan of action, recognizing
hypoglycemic symptoms and identifying available sources of glucose.
Treatment aims at restoring normal blood glucose quickly and safely, avoiding
overcorrection. Diabetes Canada CPG suggests that 15g of glucose (equivalent to 3
teaspoons of table sugar; 1 tablespoon of honey; or ¾ cup of orange juice) is efficient in
raising glycemia by 2.1mmol/L within 20 minutes. Glucagon 1mg subcutaneously or
intramuscularly produces significant blood glucose elevation (up to 12mmol/L) in 60
minutes. Recent alcohol consumption and advanced hepatic disease may impair correction
of blood glucose level.5
Clinical strategies and revised practice guidelines that accentuate the need to balance
effective glycemic control against the risk of hypoglycemia are emerging regularly.18
Adding to this, newer and safer antihyperglycemic treatments and pharmacologic
combinations are becoming more readily available. However, despite these facts, the
current burden of hypoglycemia in the real-world context still exists and has been
underestimated, especially concerning severe hypoglycemia in T2DM.11
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In the introduction of the 2018 Diabetes Canada CPG, the author advises: “People with
diabetes are a diverse and heterogeneous group; therefore, it must be emphasized that
treatment decisions need to be individualized. Guidelines are meant to aid in decision
making by providing recommendations that are informed by the best available evidence.
However, therapeutic decisions are made at the level of the relationship between the
healthcare professional and the patient. That relationship, along with the importance of
clinical judgement, can never be replaced by guideline recommendations.”3 The
cooperation that derives from a solid, genuine patient-provider relationship is indeed of
immense clinical value. Yet, sacrificing medical evidence, in the form of clinical
guidelines or expert panels for the sake of individualizing care inattentively is not aligned
with the principles of the Patient-Centered Clinical Method24 and such an attitude must not
be mistaken for patient-centeredness.
Recommendations from the 2018 CPG on hypoglycemia are listed in Appendix A.

Hypoglycemia Management in Primary
Healthcare
Management of the patient with DM embodies the spirit of primary care medicine.
Because of the chronic, progressive, and potentially disabling nature of this illness, PCP
should be at the cornerstone of diabetes care. This gate-keeping position allows
professionals to screen high-risk patients for diabetes, initiate treatment, improve
hyperglycemia, monitor and fine-tune pharmacologic therapies, and detect and manage
microvascular and macrovascular complications. While patients with complex insulin
regimens, or at risk for severe hypoglycemia, or complications often need to be referred to
specialists to assist in management, 90% of patients with diabetes can successfully be
managed in a primary care setting.25
Diabetes is an increasingly common health condition, currently affecting one in every 11
adults globally.26 It is estimated that three-quarters of people with diabetes live in low and
middle-income countries1. Ninety percent of these patients have T2DM7, and most these
individuals are cared for by non-specialist PCP.19 In Brazil, for example, diabetes is among
the five major health problems managed by PCP in community health centers.27 Yet, this
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fact also applies to developed nations such as Canada and the United States, where the bulk
of diabetes patients are cared for by PCP.11, 28, 29
Diabetes is a chronic and complex clinical condition, perhaps more common and complex
in the real-world context PCP face daily than what trial-based settings have been able to
show.30 This idea is supported by the findings of a study conducted by Bachimont in 2006
which identified that PCP were aware of the guidelines, however they found that these
guidelines sometimes disconnected from everyday practice.31
Heller argues that PCP are less confident/less knowledgeable about the risks of insulin
management and hypoglycemia when compared to specialists and thus may not be actively
and adequately assessing and managing the risk of hypoglycemia for each patient.19
Since most of the care of people with diabetes takes place in the primary care setting, there
has been a shift toward delivering diabetes care in the primary care setting using the
chronic care model.32 This model comprises an arrangement of the health system in which
the primary care provider is properly trained and well-articulated with specialists and other
actors of the healthcare system and community. There is evidence that the chronic care
model is an effective and efficient model of care for DM. 32, 33
Dovey also argues that an essential characteristic of primary care is the customization of
care to the individual patients' needs, values, and preferences across a broad spectrum of
medical care. That author states about primary care practices: “Its diversity, scope and
variation in structure and infrastructure may offer more opportunity for error than more
highly regulated and procedure-oriented hospital-based care.”34
Though the management of diabetes and its complications are widely investigated and
documented in scientific literature, little is published about how one important component
of DM, hypoglycemia, is managed in the primary care setting, and even more scarce is the
evidence around the factors that affect physician hypoglycemia management behavior and
key PCP knowledge gaps.
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The Care Gap
Numerous studies have shown that hypoglycemia is an important clinical concern for
T1DM patients and those who are T2DM on insulin and/or secretagogue agent therapy. In
general, hypoglycemia presents a barrier to starting and adjusting treatment and a challenge
in long-term adherence35, 36. Despite the evidence that tight glycemic control reduces
morbidity and mortality of DM, a significant percentage of patients do not reach treatment
goals. In the United States only 40-60% of T2DM patients reach treatment goals. In 2009,
The British National Health System (NHS), reported that two-thirds of T2DM patients
achieved the goal of 7.5% glycated hemoglobin (A1C). In Canada, the Diabetes Mellitus
Status survey35 highlighted the persistent treatment gap associated with the treatment of
T2DM and the challenges faced by primary care physicians to gain glycemic control in
these patients. Some evidence shows that the fear of a new hypoglycemic episode can
undermine patient compliance to rigorous treatment goals and lead to poor selfmanagement of the disease.36, 37, 38, 39, 40
Proper management should include a comprehensive approach and collaboration between
patients, primary care, and specialist care when appropriate.3 In North America, most of
chronic illness care, including diabetes as noted previously, occurs within the primary care
setting.29 In Canada, there is a care gap between the clinical goals outlined in evidencebased guidelines for diabetes management and real-life clinical practice.28
In summary, despite the recognition of the importance of identifying and managing
hypoglycemia as part of an overall diabetes management strategy, very little is known
about the factors that influence family physician’s attitudes and behavior in managing
hypoglycemia. This study will use newly available survey data from family physicians in
Canada to explore this prominent issue.
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2.3 Clinical Inertia
Overview
Delays in correcting prescribed treatment in T2DM patients when treatment fails to achieve
optimal glycemic control, occurs commonly in primary care settings. A substantial
proportion of people remain in poor glycemic control for several years before proper
adjustment of targets and pharmacologic treatment is initiated 41. These delays or inertia on
the part of physician to fine-tune treatment in the presence of hypoglycemia is perplexing.

Definition
The term clinical inertia was coined by Phillips in 2001.42 It refers to the situation when
there is recognition of the clinical problem (e.g. a history of hypoglycemic episodes), but
no initiative to act upon it (e.g. reticence to adjust targets or tardiness to review insulin
therapy).41, 42. O’Connor et al postulate three classes of factors leading to inertia: those
related to the patient, those related to the health system and factors related to the physician.
They estimate that these three factors contribute 30%, 20% and 50% respectively to the
phenomenon of clinical inertia.44 Factors related to the patient that are believed to be
associated with clinical inertia include denial or misconception about the disease and its
seriousness; medication nonadherence due to avoidance of expenses and/or side effects;
and resistance to adopting lifestyle adjustments that could lead to better health-related
outcomes. Factors of the system include availability of technology that optimizes clinical
reasoning and prompts specific clinical decision support; organization and
planning/prioritizing office visits according to risk, complications, results of tests; active
outreach support; availability of continuous medical education. Operationally, the
definition of clinical inertia is quite complex and all of these factors may be in play
simultaneously.44
True clinical inertia may be considered a case of medical error by omission. Dovey
conducted a study to understand the nature of medical errors from the perspectives of
family physicians.34 Family physicians were asked to describe deleterious events which
should not have occurred and which made them think: “this should not happen in my
practice, and I never want this to happen again”. He found that clinical inertia, in a broader

15

sense, was not mentioned as being part of the “taxonomy” of medical errors34. In contrast,
two other authors, also researching behavior in diabetes treatment, have clearly referred to
physician behavior falling under clinical inertia as “medical errors”.44, 45
True clinical inertia must be distinguished from watchful waiting. This attitude is a
carefully thought out decision to withhold action. Gerard Reach, in his book Clinical
Inertia46, argues that the physician behavior falls under this phenomenon of clinical inertia
if, and only if:
1.

a Guideline (G) exists, explicit or implicit

2.

the doctor (D) knows the Guideline (G)

3.

the doctor (D) thinks that this Guideline (G) applies to the patient (P)

4.

the doctor (D) has the resources to apply the Guideline (G)

5. conditions 1–4 have been met, yet the doctor (D) does not follow the Guideline (G) in
the case of the patient (P). 46 Page 10
Clinical inertia has been recognized as an important barrier contributing to inadequate
management of chronic diseases, particularly in the context of those with asymptomatic
conditions such as diabetes, hypertension, lipid disorders, where treatment decisions are
generally influenced by pondering evidence-based clinical outcomes.47

Clinical Inertia in Primary Care
A review of the literature concerning diabetes and clinical inertia reveals some relevant
research concerning management of hyperglycemia and its associations with physician
inertia in primary care settings. However, literature addressing therapeutic inertia in
management of DM related hypoglycemia in primary care, to the extent of this researcher’s
knowledge, is all but non-existent. Therefore, it is only possible to conceptualize clinical
inertia for DM care by examining the literature on clinical inertia in hyperglycemia
management.
Research with family practices in Ontario, Canada, found that insulin was underused by
PCP in patients with T2DM, even though early addition of insulin has long been an

16

efficient way to quickly and safely achieve glycemic targets and that its use has been
recommended by national and international guidelines.28 Another study in Ontario, this one
by Shah et al, identified that “fewer than one-half of patients with high A1C levels had
intensification of their medications, regardless of the specialty of their physicians.”48
A nation-wide study in Croatia aimed at understanding clinical inertia in DM management
in primary care found that clinical inertia was present in 57.7% of all clinical encounters.49
They concluded that 100% FPs were clinically inert with some patients while 9% of FPs
were clinically inert with all DM patients. Clinical inertia significantly increased in
correspondence with increasing A1C levels. Also, this research found that male family
physicians were more likely to be clinically inert than female family physicians. Another
researcher identified characteristics of the physicians who were most likely to follow
guidelines, and therefore less inclined to clinical inertia: female, recently completed
medical studies, frequently used a computer and worked in groups.50
Another interesting aspect of physician behavior that could lead to clinical inertia is the
impact of competing demands in the patient-physician encounter. Parchman51 investigated
the relationship between clinical inertia and competing demands in primary care. This
study found that among patients with an A1C level greater than 7%, each additional patient
concern was associated with a 49% reduction in the likelihood of a change in medication.
The author concluded that the concept of clinical inertia is limited and does not fully
characterize the complexity of primary care encounters.
Ziemer et al. believe that clinical inertia among PCPs is due to limited exposure to
education on target-oriented treatment and indications to treatment intensification.52 Zafar
et al. listed other factors that explain clinical inertia, some of which are directly related to
the primary care physician.41 He believes that the phenomenon of clinical inertia should be
analyzed apart from patient-related issues: i.e., it is essentially a problem of the physician
and the health care system not taking proper action in favor of the patient (Figure 2-b).
While patient non-adherence may potentiate clinical inertia on the part of the PCP, failure
to improve therapy is essentially related to physician and delivery system issues.43
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Figure 2-a: Clinical Inertia in DM Care
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Ref.: Zafar A, et al. Clinical Inertia in management of T2DM. Primary Care Diabetes, 2010

Theoretic Models of Clinical Inertia
The determinants that potentially explain clinical inertia are numerous and their interactions
are sometimes complex and difﬁcult to interpret. For this reason, the construction of
theoretical models is needed to allow a more didactic and comprehensive view. Reach46
mentions five theoretical explanatory models of clinical inertia:
•

Knowledge-Attitude-Behavior-Result Model by Cabana et al (1999)53;

•

Awareness-Agreement-Adoption-Adherence by Pathman et al (1996)54;

•

Symmetrical Model involving Physician and Patient by Kim et al (2003)55;

•

Physician Guideline Compliance Model by Maue et al (2004)56; and

•

The Regulatory Focus Theory Model by Higgins et al (1997)57.

Cabana argues that physician adherence to clinical guidelines is critical in translating
recommendations to improved patient health outcomes. In this comprehensive framework
review, the author dissects the process of decision making in guideline adherence and
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creates a theoretical framework for the baseline barriers that may undermine it and
contribute to the phenomenon of physician clinical inertia.
This model is based on the premise that the mechanism of action by which improved
patient care is achieved occurs in steps, as postulated by Woolf in 199358. Before a practice
guideline can affect patient outcomes, it must first affect physician knowledge, then
attitudes, and finally behavior. Guidelines have been considered effective not only by
measuring the outcomes, but also if they improve knowledge, making clinicians aware of
the recommendations; attitudes, getting clinicians to agree with and accept the
recommendations as a new standard of care; and behavior, getting clinicians to change
practice patterns to conform with the guidelines.58 Although behavior can be modified
without knowledge or attitude being affected, behavior change based on influencing
knowledge and attitudes is probably more sustainable than indirect manipulation of
behavior alone.53
Clinical inertia is essentially a pattern of behavior. This thesis focused on the creation of a
clinical inertia scale comprised of the elements of the actual inertia behavior in practice,
and examined potential factors that contribute to inertia.

Barriers to Behavior Change
Table 2-e synthesizes Cabana’s rational for the barriers affecting physician’s ability to act
upon a clinical problem:
Table 2-e: Barriers to Behavior Change
Intrinsic

Knowledge

Attitude

Awareness

The expanding body of research makes it difficult for
any physician to be aware of every applicable
guideline and critically apply it to practice.

Familiarity

Casual awareness does not guarantee familiarity of
guideline recommendations and the ability to apply
them correctly. Lack of familiarity is more common
than lack of awareness.

Agreement

Physicians may not agree with a specific guideline or
the concept of guidelines in general.

19

Behavior

Extrinsic

Self-efficacy

It is the belief that one can actually perform a behavior.
It influences whether a behavior will be initiated and
sustained despite poor outcomes.

Outcome
Expectancy

Is the expectation that a given behavior will lead to a
particular consequence. If a physician believes that a
recommendation will not lead to an improved outcome,
the physician will be less likely to adhere.

Inertia of
Previous
Practices

Physicians may not be able to overcome the inertia of
previous practice, or they may not have the motivation
to change behavior.

Guideline

Physicians are less likely to adhere to guidelines they
perceive as not easy to use or not convenient, or that
modify an established behavior (when compared to
ones that introduce a new behavior).

Patient

The inability to reconcile patient preferences with
guideline recommendations is a barrier to adherence.

Environment/System

Adherence to practice guidelines may require changes
not under physician control, such as acquisition of new
resources or facilities.

Ref.: Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud P-AC, Rubin HR. Why don’t physicians follow
clinical practice guidelines? A framework for improvement. JAMA. 1999; 282:1458–67.

The Challenge
Though the management of diabetes and its complications are widely investigated and
documented in scientific literature, there is insufficient evidence about how hypoglycemia
is managed in a primary care setting. In addition, it seems that what is considered in the
literature as clinical inertia (that is, physicians not taking action in clinical circumstances
that current guidelines clearly indicate action is recommended) is an acknowledged event in
primary care medicine and that its frequency and consequences make it a major public
health problem. The objective of this thesis was to develop a measure of clinical inertia
specific to hypoglycemia and, by using that measure, gain an understanding about the
factors that influence clinical inertia behavior in family physicians in the management of
hypoglycemia.
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Chapter 3
Methodology
This thesis was a secondary analysis of a sub-set of data collected in the project entitled
“UnderstandINg the impact of HYPOglycemia on Diabetes Management: A Survey of
Perspectives and Practices” (InHypo-DM Study).

3.1 Study Objectives
This study had two objectives.
1. The first objective was to determine the factor structure for the construct of clinical
inertia around family physicians’ behavior in managing hypoglycemia in their
diabetic patients, in the primary care setting.
2. Should a robust factor structure be found for clinical inertia, the second objective
was to determine if there was a correlation between physician clinical inertia and
family physician characteristics.

3.2 Study Design
This study was an exploratory factor analysis using secondary data from a cross-sectional
family physician self-reported survey about hypoglycemia management. Data was
obtained from the InHypo-DM Study.

3.3 Data Source: The InHypo-DM Study
InHypo-DM Study Overview
The InHypo-DM Study was the largest hypoglycemia research program conducted in
Canada to date.11 This study was initiated across Canada in 2014 and data analysis is
ongoing to the present date. The data used in this thesis were collected from February to
April 2016. It was an investigator-initiated research study conducted by Dr. Stewart Harris
and collaborators at Western University. It explored clinical and personal perspectives, and
practices and behaviors related to hypoglycemia in diabetes, as well as factors influencing
hypoglycemia management from the perspectives of three distinct populations: patients
with DM, people who have a significant other with DM, and healthcare providers (HCP).
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InHypo-DM: Methodology
The InHypo-DM Study used a mixed-methods approach with quantitative and qualitative
methods used at distinct stages of the project. Initially, a comprehensive literature review
was conducted and 87 questionnaires were identified, from which 2035 questions were
extracted and categorized by specific domains.

InHypo-DM: Theoretical Domains Framework
Tool
A validated tool, the Theoretical Domains Framework (TDF)59, was employed in the
development of interview guides for a sample of key informants: patients with DM (DM),
their significant others (SO) and healthcare providers (HCP). Given the complexity of the
management of hypoglycemia, and the limited understanding of it thus far, the TDF tool
became especially useful for determining the psychosocial, situational, organizational, and
environmental determinants of behavior. Qualitative interviews with DM, SO and HCP
were conducted to explore their knowledge, experiences, and opinions regarding
hypoglycemia management.

InHypo-DM: Questionnaires
Questionnaires for the three population groups (DM, SO, HCP) were developed using the
knowledge from the literature review and the key informant interview, while guided by the
TDF. Responses were formulated using 5-point Likert Scales. These questionnaires were
piloted for feedback on relevance, clarity, and quality of response options.
The HCP questionnaire (Appendix B) was developed to explore factors that impact HCP
potential to effectively help people with diabetes manage hypoglycemia and included a
socio-demographic and professional profile segment (section 9) and eight sections on
practices and opinions about hypoglycemia management: 1) Knowledge, 2) Capability, 3)
Practice, 4) Support, 5) Views, 6) Effects of work life and 7) Effects of social relationships,
and 8) Worry/frustration. Respondents included Endocrinologists, Family Physicians,
Nurse Practitioners, Registered Nurses, Dietitians, and Pharmacists who provide diabetes
care. Appendix contains the entire In-Hypo DM HCP questionnaire.
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InHypo-DM: HCP Sampling
A total of 9163 e-mails were sent with an invitation to participate in the study and a link to
the HCP questionnaire. The sources for the distribution of the online survey were: a) a
panel of physicians and pharmacists who provide diabetes care administered by
Professional Targeted Market (PTM), counting 5579 contacts, or 60.9%; and b) the
professional section of the Canadian Diabetes Association registered diabetes educators and
physicians/researchers (CDA), counting 3584 contacts, or 39.1%. The sampling service
utilized multi-source recruitment, quota sampling and quality monitoring. Those who fully
completed the questionnaire totalled 671 respondents among physicians and other allied
healthcare providers. The diagram in Figure 3-a details the sampling steps:

23

Figure 3-a: Consort Diagram for the In-HypoDM Study, HCP sampling

Email invites n=9.163
(5.579 PTM; 3.584 CDA)

Hard-bounced
n=661
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Physician n=194

Complete n=671

Dietitian n=110

Pharmacist n=68

Other n=50

Family Physician
n=162
Diabetes Specialist
Family Physician
n=9
Endocrinologists
n=14
Other n=9

N= total number; PTM = Professional Targeted Marketing; CDA = Canadian Diabetes Association
Ref.: Investigating the impact of hypoglycemia on diabetes management: A survey of perspectives and practices.
(InHypo-DM Study) Final report phase I & II, 2016.

InHypo-DM: HCP Respondents – Descriptive
Results
The respondents included: physicians (28.9%) and other healthcare providers: nurse (nurse
practitioners and registered nurses) (37.1%), dietitians (16.4%), and pharmacists (10.1%).
The profile of HCP respondents overall was as follows: the majority were female (75%),
the average age was 53 years, they were practicing for an average of 16 years, the majority
(69.4%) practiced in an urban setting and the majority (65.7%) were Certified Diabetes
Educators (CDE or, in this paper, also referred to as Diabetes Educator designation).
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Respondents saw an average of 28 patients with diabetes per week and 15.7% of these
people had been diagnosed with T1DM.
One hundred and ninety-four physicians completed the questionnaire: 162 family
physicians, 14 endocrinologists, 9 diabetes specialist family physicians, 4 internal medicine
and 5 respondents from other medical categories. The physician respondents’ (28.9%)
profile was: male (57%), average age of 56.7 years, few (6%) were Certified Diabetes
Educators, practicing for an average of 26 years, in an urban setting (77.3%), seeing an
average of 31 patients with diabetes per week. Only 6% of the physicians were CDE.
Table 3-a shows a comparison of HCP respondent profile and the physician respondent
profile.
Table 3-a: Comparison of Other Health Care Provider and Physician Characteristics
HCP
Physician
Respondents Respondents
(n=671)
(n=194)
Sex (%)
75
57
Age in years (mean)
53
56.7
Diabetes Educator designation (%)
65.7
6
Years in practice (mean)
16
26
# DM pt/week (mean)
28
31
N = total number; DM = Diabetes Mellitus; pt = patient
Ref.: Investigating the impact of hypoglycemia on diabetes management: A survey of perspectives and practices.
(InHypo-DM Study) Final report phase I & II, 2016.

3.4 Sample
The sample for this thesis consisted of the sub-set of 162 family physicians who completed
the InHypo-DM HCP questionnaire.

3.5 Variables
Dependent Variable
The first objective of this thesis was to create a clinical inertia scale. The potential items for
inclusion in the scale were the 13 questions in section 3 that asked family physicians about
what they believed to be true about their actual practices and behavior. The heading for
this section of the questionnaire read: “These are questions about what you do when
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helping your patients manage their hypoglycemia. Remember that management refers to
both treatment and prevention. Please select the answer that you believe is true most of the
time:”
Table 3-b reproduces the 13 items in Section 3 from the questionnaire. The response
categories in the 5-point Likert scale were: “Never”; “Rarely”; “Sometimes”; “Often”; and
“Always”.
Table 3-b: Potential Items for the Clinical Inertia Scale
Section 3 – These are questions about what you actually do when helping Name of variable for
your patients manage their hypoglycemia. Remember management refers to this thesis
both treatment and prevention. Please select the answer that you believe is
true most of the time:
In general,
10) …I make an effort to keep track of my patients’ progress with regard to effort track progress
managing their hypoglycemia.
11) …I advise my patients to increase the frequency of blood glucose monitoring advice
when they are at increased risk for hypoglycemia.

increase

monitor

12) …I make sure that I am prepared to help my patients manage their prepared to help
hypoglycemia.
13) …I am confident that I can help my patients manage their hypoglycemia even time management
when there is little time.
14) …addressing the specific appointment issue takes priority over discussing their specific issue priority
hypoglycemia management.
15) …helping my patients manage their hypoglycemia is something I do routinely. routine help
16) …the way I help my patients manage their hypoglycemia is informed by current guideline informed
evidence and guidelines.
17) …I take the initiative to help my patients improve their hypoglycemia take initiative
management.
18) …I explain how to manage hypoglycemia to my patients.

explain how manage

19) …I discuss hypoglycemia-related guidelines regarding driving or operating discuss guidelines
heavy machinery with my patients.
20) …I solicit patients’ input when discussing their hypoglycemia management.

solicit input

26

21) …I use motivational strategies to help my patients manage their hypoglycemia. motivational strategy
22) …my professional liability, according to my specific regulatory body, directs professional liability
the way I manage patients’ hypoglycemia.

Independent Variables
Ref.: Investigating the impact of hypoglycemia on diabetes management: A survey of perspectives and practices.
(InHypo-DM Study) Final report phase I & II, 2016. InHypo-DM HCP questionnaire, Section 3

The independent variables used in this analysis were:
a) Age in years,
b) Sex (male, female),
c) Years in practice,
d) Practice location (rural or urban setting),
e) Canadian province where the practice was located (recoded into the following categories:
Ontario (ON); Quebec (QU); Newfoundland (NL); Alberta (AB); Western/Prairie
Provinces – British Columbia (BC), Manitoba (MB) and Saskatchewan (SK); and Maritime
Provinces – Prince Edward Island (PEI), New Brunswick (NB) and Nova Scotia (NS).
f) Practice type (response options in the questionnaire were Hospital, Family Health Team
or Other. The answers for the open-text option Other included: Family Health
Organizations or Groups; Primary Care Network, solo/private office; Community Health
Clinic/walk-in clinic, corporate clinic, military Clinic, long-term care and palliative
facilities, and retirement homes. All responses were recoded as “Hospital”, “Team-based
practice” and “non-Team based practice”),
g) Diabetes Educator designation (yes or no),
h) Country where the respondent obtained the most recent professional degree, (Canada or
other)
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i) Mean number of diabetes patients the respondent physician usually sees in an average
week (# DM pt/week),
j) Personal diagnosis of diabetes (yes or no).

3.6 Descriptive Analysis
A descriptive analysis examined the distribution of all variables. The frequencies and
percentages for the response for each of the 13 potential clinical inertia items were run, and
missing values were identified. For the independent variables, the mean and standard
deviation were calculated for age, years in practice and number of DM patients per week.
For the remaining independent variables, sex, practice type, practice location, province of
practice, country of medical degree, DM educator designation, and personal diagnosis of
diabetes, frequencies and percentages were run. All analyses were conducted using SPSS
statistics version 25.

3.7 Exploratory Factor Analysis
Exploratory Factor Analysis (EFA) was the chosen statistical technique to address the first
objective of this study, to create a clinical inertia scale. There are two main purposes or
applications of factor analysis: data reduction and exploring theoretical underlying
structures. It allows the researcher to examine all relationships between individual variables
(items on a scale), grouping together variables that are correlated in order to extract latent
factors. These factors should reflect the underlying processes that have created the
correlations among variables. “Exploratory factor analysis is usually performed in the early
stages of research, when it provides a tool for consolidating variables and for generating
hypothesis about underlying processes.”60 EFA is normally the first step in building scales
or new metrics.61 Exploratory factor analysis was used in this thesis in an iterative process
to identify correlations among the 13 potential clinical inertia items that could contribute to
a clinical inertia scale.
The following sections 3.7.1 and 3.7.2 outline the assumptions that were explored before
determining whether the data set was suitable for EFA.

28

Adequacy of Sample
Exploratory Factor Analysis requires a robust sample size and a strong correlation among
variables in the data set. Adequacy of the sample was verified by the Bartlett´s test of
Sphericity and the Kaiser-Meyer-Olkin (KMO) measures. The strength of the
intercorrelations among items (referred to as factorability) was verified by examining the
correlation matrix.
Bartlett’s test of Sphericity tests whether the data comes from multivariate normal
distribution with zero covariances or, in other words, the correlation matrix is an identity
matrix. This would indicate that the factor model is inappropriate. It is appropriate if p <
0.05.60 The KMO measure of sampling adequacy ranges from 0 to 1. A minimum value
suggested for a good factor analysis is 0.6.60
For a data set to be suitable for EFA, or to achieve factorability, the items in the sample
must have strong correlations. The correlation matrix was used to identify the value of
correlations between variables. Strong correlations are indicated by coefficients greater
than 0.3.60

Data Verification
The missing values were treated using the exclude case listwise option in SPSS. With this
option, cases were included in the analysis only if they had full data on all the variables
listed for that analysis.
Normality assessment was performed with the Kolmogorov-Smirnov and Shapiro-Wilk
tests. The Kolmogorov-Smirnov statistic assesses the normality of the distributions of the
scores. A non-significant result (value greater than 0.05) indicates normality. On the other
hand, a significant value less than 0.05 suggests a violation of the assumption of normality.
The Shapiro-Wilk test rejects the hypothesis of normality when the p-value is less than or
equal to 0.05.
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Extraction and Rotation Methods
The extraction method for this study was the Principal Axis Factors (PAF) technique,
chosen because the 13 potential clinical inertia items included in the EFA were not
normally distributed. Maximum likelihood extraction method is preferred when
multivariate normality of the variables is observed and PAF for when that assumption is
violated.61, 62
Rotations were performed after extraction in an attempt to find the clearest and simplest
structure for ease of interpretation. This is achieved by maximizing high correlations
between factors and minimizing low ones through mathematical procedures. The types of
rotations are distinguished in terms of whether they are orthogonal, used when it is believed
that factors are uncorrelated, or oblique, used when it is believed that the factors are
correlated.63 According to Osborne, “In the social sciences we generally expect some
correlation among factors, particularly scales that reside within the same
instrument/questionnaire, …, and oblique rotation should theoretically render a more
accurate, and perhaps more reproductible solution.”62 page 33
In this EFA, the SPSS output for Oblique rotations (correlated items), provided two tables
of loadings: A Pattern Matrix and a Structure Matrix. The structure matrix disregards the
fact that the factors are correlated and the differences between high and low loadings are
more apparent in the pattern matrix. The greater the loading, the more the variable is a pure
measure of the factor. Some authors suggest that loadings over 0.71 are excellent, over
0.63 are very good, over 0.55 are good, over 0.45 are fair and under 0.32 are poor.60 For
this thesis, based on statistical advice from supervisors, values above 0.40 were considered
adequate loadings. When no rotation is performed, only one matrix is presented, a Factor
Matrix.

Factor Retention
The decision on how many of the extracted factors to keep was guided by the scree plot and
the Kaiser’s criterion (eigenvalue and the total variance explained). Some authors
recommend using the scree test in conjunction with the eigenvalues to determine the
number of factors to retain.61, 62
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The Scree test involves plotting the eigenvalues of each factor and inspecting the plot to
find a point where the shape of the curve changes direction or inclination abruptly. Factors
that should be retained are those that lie above the point where the line changes
inclination.64
The Kaiser’s criterion, or the eigenvalue rule, is the most commonly used technique to
decide how many factors to retain.64 Using this rule, only factors with an eigenvalue of 1.0
or higher are retained for further investigation. The eigenvalue of a factor represents the
amount of the total variance explained by that factor.
Once the number of factors was defined, investigation continued with interpreting the
findings to make clinical sense. This is an essential step in EFA. The interpretation is
conducted to understand the underlying dimensions that unify the group of variables that
load on each factor.60
The strength of the relationship between the factors is measured by the value on the Factor
Correlation Matrix. Values above 0.3 are considered strongly correlated. Values above 0.8
may be considered, in fact, too highly correlated, suggesting that they are indistinct and
might actually fit better as a sub-scale of one single factor.65
One of the most commonly used indicators of internal consistency is Cronbach’s alpha
coefficient. Internal consistency for each factor was assessed by checking the coefficient
value of each factor’s Cronbach’s alpha. Ideally, the Cronbach’s alpha coefficient should be
above 0.7.64

3.8 Clinical Inertia Score
Factor Score
A factor score is a useful outcome of EFA. Factor scores can be calculated in various
forms. They are estimates of the scores that subjects would have received on each of the
factors had it been possible to measure them directly. The simplest procedure for achieving
this is to calculate the mean value of each responses in the questionnaire for each
respondent.60 This method was used to calculate a clinical inertia score which was then
treated as a continuous outcome variable.
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3.9 Examining the Relationship between the Clinical Inertia
Score and Physician Characteristics
Bivariate Analysis
The relationship between the clinical inertia score and physician characteristics was
examined first using bivariate statistics and then using multiple linear regression. The
independent variables used to compare physician characteristics to the factor score were:
age, sex, years in practice, country of medical degree, practice location (urban or rural),
Province of practice, practice type (team-based or non-team-based), Diabetes educator
designation, number of DM patients per week and personal diagnosis of DM.
Normality for continuous variables and Outcome variable (12-item Score) was assessed by
Shapiro-Wilk and Kolmogorov-Smirnov tests and verified by examining in the Quartile (QQ) Plots. When distribution of points on the scatterplot form a linear trace, it is presumed
that the assumption of normality was not violated.
For the bivariate analysis, the procedures were Pearson correlation for continuous
independent variables (age, years in practice, number of DM patients per week),
independent-samples t-test for dichotomous independent variables (sex, practice location,
country of medical degree, Diabetes educator designation), and ANOVA for categorical
independent variables with more than two response categories (practice type, Province of
practice).

Multiple Linear Regression
The primary goal of regression analysis is to investigate the relationship between a
dependent variable (in this case, the clinical inertia score) and several independent
variables.
Standard multiple regression was performed to explore the relationship between the clinical
inertia factor score and all independent variables in the model. Assumptions underpinning
multiple linear regression were tested as follows:
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The adequacy of the sample size was assessed by applying the formula (n ≥ 20 + 5m)
where m = number of Independent variables (IV).64
Absence of multicollinearity was determined by examining the correlation matrix and
variables with a bivariate correlation of 0.7 or more were considered collinear and removed
from the regression.64
Absence of Outliers was verified by inspecting the standardised residual scatterplot for
values beyond ± 3.3.64
Normality, linearity and homoscedasticity of residuals refer to aspects of distribution of
scores and the nature of the underlying relationship between variables. The assumptions of
linearity and normality were checked by visually inspecting the Normal Probability (P-P)
Plot of the regression standardised residuals for a reasonably straight diagonal line from
bottom left to top right, indicating no major deviations from normality.64
Homoscedasticity was assessed by inspection of the scatterplot. When the residuals were
roughly rectangularly distributed with most scores concentrated in the center, it determines
that the variance of the residuals about the predicted outcome variable scores were the same
for all predicted scores and the assumption of homoscedasticity was met.64
The mode ENTER was the model choice, and only entries with full data were included.
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Chapter 4
Results
This chapter first describes the sample of family physician respondents. Next, results from
the Exploratory Factor Analysis are reported. Finally, the resulting clinical inertia score is
compared to the characteristics of the family physicians in both bivariate and multivariate
analyses.
Important note: Data analysis was processed by SPSS with Brazilian Portuguese
(European) convention for punctuation, where decimals points are represented by commas,
not by periods, as in the English convention. Most tables in this chapter must be read with
this understanding.

4.1 Family Physician – Descriptive Results
One hundred and sixty-two family physician (FP) or primary care physicians (PCP)
(hereafter referred to as family physicians or FPs) completed the questionnaire. Table 4-a
and Table 4-b report on the continuous and the categorical variables respectively. These
respondents were 56.2% males, 43.8% females with a mean age of 57.5 years. Respondents
had been practicing medicine for a mean of 26 years. The number of DM patients seen by
these FP was, on average, 27 DM patients per week. One family physician respondent
reported seeing an average of 250 DM patients per week. This respondent also informed
that he/she is not a diabetes educator and works in a Family Health Team. That number of
DM patients/week was deemed highly improbable and was considered an error and it was
excluded from the analysis. Nine respondents (5.6%) affirmed having a Diabetes Educator
designation.
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Table 4-a: Family Physician Respondent Characteristics – Continuous Variables

Mean SD
Age in years
57.55 9.65
Years in practice 26
11
# DM pt/week
27
24

25th
75th
Min percentile Median percentile Max
31
3
1

50
17
12

57
25
20

64
33
30

85
55
101

SD = Standard Deviation; Min = Minimum; Max = Maximum; DM = Diabetes; pt = patient

The majority, 75.3%, of FPs were in urban areas and 24.7% in rural areas. FPs reported that
they practiced in Hospitals (4.9%), Family Health Teams (30.9%) or Other settings
(64.2%). Nine respondents did not specify the type of their practice. After recoding this
variable into Hospital, Team-based and not-Team based, the distribution was Hospitals
(5.4%), Team-based practice (42,3%) and Non-Team-based practice (46.3%).
Most FP respondents practiced in Ontario (54.7%), Canada’s most populated province.
The distribution of FP respondents (159 valid responses) across Canada is represented in
Figure 4-a.
The majority of respondents obtained their degree in Canada (84.5%). Fifteen per cent of
the FP obtained their degree in other countries including respondents from the United
Kingdom, India, Ireland, South Africa, Slovakia, Uganda, Hong Kong, USA, Jordan,
Bangladesh, Pakistan and Libyan Arab Jamahiriya.
Nine percent of the FP respondent had a personal diagnosis of DM, of which 46% reported
having experienced a diabetes-related hypoglycemic event.
The distribution for each categorical variable, including re-coded Province and Practice
type variables, are presented in Table 4-b.
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Figure 4-a: Distribution of FP Respondents across Canada (%)

Note: Decimals in this graph are represented by commas, not periods. Western/Prairies = British Columbia, Manitoba and
Saskatchewan; Maritimes = Prince Edward Island, New Brunswick and Nova Scotia
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Table 4-b: Family Physician Respondent Characteristics – Categorical Variables
Location Urban
Rural
Province ON
QU
NL
AB
Western/Prarie
Provinces
Maritimes
Provinces
Practice Hospital Practice
Type
Team-based
Practice
Not Teambased Practice
Missing
Country Canada
of Degree Other Country
CDE
Yes
No
Personal Yes
DM
No

Count

% of N

122
40
87
13
18
12
17

75,3%
24,7%
54,7%
8,2%
11,3%
7,5%
10,7%

12

7,5%

8

5,4%

63

42,3%

69

46,3%

9
136
25
9
153
14
148

6,0%
84,5%
15,5%
5,6%
94,4%
8,6%
91,4%

Note: Decimals in this table are represented by commas, not periods. N= total number; CDE = Diabetes Educator
designation; ON = Ontario; QU = Quebec; NL = Newfoundland; AB = Alberta; WP = Western Prairies (British
Columbia, Manitoba and Saskatchewan); MP = Maritime Provinces (Prince Edward Island, New Brunswick and Nova
Scotia); DM = Diabetes

4.2 Exploratory Factor Analysis
Adequacy of Sample
Prior to performing EFA, the suitability of the data for factor analysis was assessed.
Inspection of the correlation matrix revealed the presence of many coefficients of 0.3 and
above indicating the factorability of the items (Table 4-c). The KMO index was 0.923,
achieving the recommended value of 0.6 or higher, and Bartlett`s test of Sphericity reached
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statistical significance (p < .001), supporting the adequacy of sample size and factorability
of the correlation matrix (Table 4-d).
Table 4-c: Correlation Matrix
effort
advice
time
specific
explain
prepared
routine guideline take
discuss solicit
track
increase
manag issue
how
to help
help informed initiative
guidelines input
progress monitor
ement priority
manage
effort track progress
advice increase monitor
prepared to help
time management
specific issue priority
routine help
guideline informed
take initiative
explain how manage
discuss guidelines
solicit input
motivational strategy
professional liability

1,000
0,447

1,000

0,563

0,557

motivatio professio
nal
nal
strategy liability

1,000

0,521

0,418

0,645

1,000

-0,061
0,550

-0,121
0,388

-0,183
0,650

-0,172
0,575

1,000
-0,224

1,000

0,470

0,415

0,551

0,570

-0,118

0,585

1,000

0,532

0,488

0,691

0,596

-0,105

0,739

0,628

1,000

0,561
0,405

0,461
0,397

0,645
0,424

0,551
0,459

-0,142
-0,124

0,655
0,475

0,545
0,477

0,689
0,511

1,000
0,524

1,000

0,531

0,409

0,507

0,517

-0,206

0,491

0,507

0,608

0,571

0,539

1,000

0,417

0,317

0,485

0,617

-0,048

0,485

0,433

0,579

0,535

0,521

0,581

1,000

0,286

0,131

0,300

0,314

0,111

0,302

0,344

0,419

0,265

0,376

0,344

0,404

Note: Decimals in this table are represented by commas, not periods.
Values > |0.30| considered well correlated

Table 4-d: Sample Adequacy tests
KMO and Bartlett Tests
Kaiser-Meyer-Olkin Measure
of sample
Bartlett`sadequacy
Aprox. QuiSphericity

0,923
1076,646

squared

Test
Sig.

0,000

Note: Decimals in this table are represented by commas, not periods. Sig = Significance

Data Verification
The cases were inspected for missing data. Two cases of missing data were found, where
respondents chose not to answer a question that was expected to be answered by all
respondents. These two cases were excluded from the factor analysis.

1,000
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The Kolmogorov-Smirnov and Shapiro-Wilk statistic tests assess the normality of the
distribution of scores. For these tests, the significance value across the table is 0.000,
suggesting violation of the assumption of normality. Table 4-e reports the test for each of
the 13 potential items. This result dictated the choice of extraction method as outlined in
next section, 4.3.1.
Table 4-e: Normality Tests
Kolmogorov-Smirnov
Statistic

df

a

Shapiro-Wilk
Sig.

Statistic

df

Sig.

effort track progress

0,253

160

0,000

0,860

160

0,000

advice increase monitor

0,248

160

0,000

0,804

160

0,000

prepared to help

0,274

160

0,000

0,808

160

0,000

time management

0,277

160

0,000

0,849

160

0,000

specific issue priority

0,201

160

0,000

0,901

160

0,000

routine help

0,247

160

0,000

0,870

160

0,000

guideline informed

0,311

160

0,000

0,831

160

0,000

take initiative

0,338

160

0,000

0,815

160

0,000

explain how manage

0,285

160

0,000

0,830

160

0,000

discuss guidelines

0,253

160

0,000

0,874

160

0,000

solicit input

0,289

160

0,000

0,831

160

0,000

motivational strategy

0,281

160

0,000

0,862

160

0,000

professional liability

0,189

160

0,000

0,909

160

0,000

Note: Decimals in this table are represented by commas, not periods. Df = degrees of freedom; Sig = significance

4.3 Factor Analysis – Round 1
EFA-1 Extraction and Rotation Methods
Based on the assessment described in Section 4.2, the data were considered suitable to
proceed with the EFA. The chosen extraction method was the Principal Axis Factors (PAF)
technique, due to the observation that there was not a normal multivariate distribution.
Rotation was performed for achieving a simpler structure, for ease of interpretation.
Because the 13 potential clinical inertia items were correlated, the oblique technique of
rotation Oblimin was chosen. The Pattern and Structure matrices report all factor loadings
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for each of the 13 potential clinical inertia items on each factor (Table 4-f). Factor loading
values of 0.40 and above are considered relevant.
This first round of Exploratory Factor Analysis revealed the presence of two factors with
eingenvalues above 1; and one factor with eigenvalue inferior to 1. The eingenvalues for
the three factors found were 4.582 (factor #1), 1.356 (factor #2) and 0.824 (factor #3). It is
recommended that only factors with eingenvalues of 1 or above should be retained.61 These
3 factors explained 46.36%, 13.726%, 8.34% of the variance, respectively, and 68.43%
cumulatively. Table 4-g presents these results.
An inspection of the scree plot (Figure 4-b) revealed a break in the inclination of the
graphic line after the second factor (#2), further corroborating that factor #3 should be left
out of the analysis.
Table 4-h reports the factor correlation values in the 3-factor solution, showing a strong
negative correlation between factor #1 and factor #3 and a weak negative correlation
between factor #1 and factor #2. Factors #2 and #3 had a weak positive correlation.
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Table 4-f: Pattern and Structure Matrix for EFA-1 with Oblimin Rotation
Pattern coefficients

Variable
effort track progress
advice increase monitor
prepared to help
time management
specific issue priority
routine help
guideline informed
take initiative
explain how manage
discuss guidelines
solicit input
motivational strategy
professional liability

Structure coefficients

Factor 1

Factor 2

Factor 3

Factor 1

Factor 2

Factor 3

0,666
0,603
0,966
0,521
-0,018
0,766
0,557
0,735
0,701
0,076
0,134
0,117
0,020

-0,053
0,049
0,158
-0,254
0,020
-0,022
-0,199
-0,180
-0,107
-0,630
-0,617
-0,661
-0,570

0,074
-0,064
0,026
-0,077
0,563
-0,065
0,009
0,094
-0,045
-0,132
-0,246
-0,021
0,258

0,684
0,585
0,840
0,733
-0,197
0,801
0,703
0,842
0,793
0,584
0,667
0,617
0,371

-0,548
-0,403
-0,563
-0,645
0,049
-0,596
-0,615
-0,726
-0,631
-0,690
-0,724
-0,749
-0,578

-0,120
-0,238
-0,250
-0,235
0,569
-0,288
-0,157
-0,124
-0,251
-0,170
-0,301
-0,072
0,237

Communalities
0,475
0,348
0,716
0,564
0,325
0,646
0,512
0,738
0,634
0,501
0,611
0,569
0,398

Note: Decimals in this table are represented by commas, not periods. Values > |0.40| are considered adequate loadings

Table 4-g: Total Variance Explained EFA-1
Initial Eigenvalues

Factor

1
2
3
4
5
6
7
8
9
10
11
12
13

Total

% of Variance

Cumulative %

4,582
1,356
0,824
0,598
0,457
0,403
0,355
0,150
0,303
0,205
0,199
0,155
0,131

46,362
13,726
8,342
6,049
4,620
4,081
3,588
3,188
3,063
2,074
2,011
1,566
1,329

46,362
60,088
68,430
74,479
79,099
83,180
86,768
89,956
93,019
95,093
97,104
98,671
100,000

Rotation
Sums of
Squared
Loadings
Total
4,215
2,258
0,511

Note: Decimals in this table are represented by commas, not periods.
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Figure 4-b: Scree plot EFA-1

Note: Decimals in this graph are represented by commas, not periods.

Table 4-h: Factor correlation Matrix EFA – 1
Factor Correlation Matrix
Factor

1

2

3

1

1,000

-0,290

-0,747

2

-0,290

1,000

0,026

3

-0,747

0,026

1,000

Note: Decimals in this table are represented by commas, not periods.

Retaining Factors
With the support of the results of these tests, it was decided to retain factor #1 and factor #2
for further investigation. The third factor was composed of one variable, item #14 of the
questionnaire. This variable was separated from the analysis and was the subject of further
examination, reported at the end of this study.
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4.4 Factor Analysis – Round 2
EFA -2 Extraction and Rotation Methods
A second factor analysis was run, without the one variable that composed factor #3, leaving
12 items. In order to maximize high correlations between factors and potential clinical
inertia items and minimize low correlations between them, rotation was performed and,
again, the oblique technique Oblimin allowed for a better clustering of items and therefore
better interpretation. The rotated solution revealed the presence of simple structure, with
both factors showing a number of strong loadings predominantly on only one factor on the
Pattern Matrix. All factors were internally consistent and well defined by the variables. In
Table 4-i, good loading values, 0.45 or above, are bolded for ease of interpretation.
The two-factor solution explained a total of 63.7% of the variance (Table 4-j), with factor 1
contributing to 52.4% and factor 2 contributing to 11.3%, as shown in the Table 4-j.
The scree plot on for this second round of factor analysis confirmed the two-factor solution.
After rotation, the Factor Correlation Matrix, also referred to as Component Correlation
Matrix (Table 4-k) showed a strong negative correlation between the two factors, at -0.707.
Internal reliability for each factor was calculated and found to be satisfactory with a value
of 0.910 for Factor #1 and 0.762 for Factor #2. The Cronbach Alpha`s value for the 12
items together was 0.915. (Table 4-l)
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Table 4-i: Pattern and Structure Matrix for EFA-2 with Oblimin Rotation
Pattern coefficients

Variable
effort track progress
advice increase monitor
prepared to help
time management
routine help
guideline informed
take initiative
explain how manage
discuss guidelines
solicit input
motivational strategy
professional liability

Structure coefficients

Factor 1

Factor 2

Factor 1

Factor 2

0,636
0,682
0,908
0,550
0,748
0,541
0,639
0,741
0,204
0,340
0,141
-0,057

-0,074
0,112
0,101
-0,251
-0,059
-0,222
-0,267
-0,083
-0,534
-0,462
-0,661
-0,587

0,698
0,790
0,836
0,688
0,828
0,602
0,727
0,800
0,582
0,358
0,608
0,666

-0,605
-0,588
-0,541
-0,523
-0,719
-0,370
-0,639
-0,607
-0,679
-0,546
-0,761
-0,702

Communalities
0,476
0,369
0,705
0,560
0,625
0,512
0,721
0,644
0,482
0,551
0,589
0,300

Note: Decimals in this table are represented by commas, not periods. Values > |0.40| are considered adequate loadings

Table 4-j: Total variance Explained EFA-2
Initial Eigenvalues

Factor

1
2
3
4
5
6
7
8
9
10
11
12

Total

% of Variance

Cumulative %

4,543
0,979
0,602
0,457
0,406
0,355
0,317
0,303
0,215
0,200
0,156
0,135

52,403
11,297
6,947
5,266
4,684
4,095
3,660
3,495
2,484
2,312
1,801
1,556

52,403
63,699
70,646
75,912
80,597
84,692
88,352
91,847
94,332
96,643
98,444
100,000

Rotation
Sums of
Squared
Loadings
Total
4,336
2,439

Note: Decimals in this table are represented by commas, not periods.
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Figure 4-c: Scree plot EFA-2

Eigenvalue

Screeplot
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Factor number
Note: Decimals in this graph are represented by commas, not periods.

Table 4-k: Factor Correlation Matrix EFA-2
Factor Correlation Matrix
Factor

1

2

1

1,000

-0,707

2

-0,707

1,000

Note: Decimals in this table are represented by commas, not periods.

Table 4-l: Cronbach`s Alpha EFA -2
Reliability

Cronbach's
alpha

Cronbach's alpha
(standardized Number of
items)
items

Factor 1

0,910

0,910

8

Factor 2
2-Factor
solution

0,762

0,773

4

0,915

0,921

12

Note: Decimals in this table are represented by commas, not periods.
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Factors in EFA - 2
Table 4-m lists variables that composed factor #1, in order of importance (highest to lowest
loading values, on the pattern matrix).
Table 4-m: Loading values (Pattern coefficients) for variables in EFA-2 Factor #1
Loading Value
0.908
0.748
0.741
0.682
0.639
0.636
0.550
0.541

Item
I make sure that I am prepared to help my patients manage their hypoglycemia.
helping my patients manage their hypoglycemia is something I do routinely.
I explain how to manage hypoglycemia to my patients.
I advise my patients to increase the frequency of blood glucose monitoring when they are at increased risk for hypoglycemia.
I take the initiative to help my patients improve their hypoglycemia management.
I make an effort to keep track of my patients’ progress with regard to managing their hypoglycemia.
I am confident that I can help my patients manage their hypoglycemia even when there is little time.
the way I help my patients manage their hypoglycemia is informed by current evidence and guidelines.

Table 4-n lists variables that composed factor #2, in order of importance (highest to lowest
loading values, on the pattern matrix).
Table 4-n: Loading values (Pattern coefficients) for variables in EFA-2 Factor #2
Loading Value
-0,661
-0.587
-0.534
-0.462

Item
I use motivational strategies to help my patients manage their hypoglycemia.
My professional liability, according to my specific regulatory body, directs the way I manage patients’ hypoglycemia.
I discuss hypoglycemia-related guidelines regarding driving or operating heavy machinery with my patients.
I solicit patient’ input when discussing their hypoglycemia management.

Although the two factors found were statistically distinguished, they were not clinically
distinct; they did not describe two different concepts within the overarching theme of
clinical inertia. With that in mind, this overlap in construct was discussed with the clinician
supervisor and we determined that it was appropriate to evaluate the use of a scale with all
the items as one factor, instead of a two-factor scale.

4.5 Factor Analysis – Round 3
In Round 3, another EFA was conducted restricting the analysis to one factor. Note that
with a one-factor solution, there is no rotation. When there are several loadings on the
factor matrix that have adequate values (greater than 0.40), it is evidence that one-factor
scale is reasonable.
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One Factor Solution – 13 item scale
This 13-item solution (Table 4-p) explained 50.1% of the variance (Table 4-p). However,
the item that was found inconsistent in previous EFA-1 for loading on a factor alone, in this
round of EFA also showed inappropriate loading value, that is, smaller than 0.30. This
item, #14 “appointment issues take priority”, had a loading value of – 0.174, and it was
removed from the analysis and therefore not used in the scale. Another round of EFA was
run without that item.
Table 4-o: Factor Matrix EFA – 3 (One-factor, 13-item)
Factor Matrix
Factor

1
effort track progress

0,680

advice increase monitor
prepared to help

0,566
0,792

time management
specific issue priority
routine help
guideline informed
take initiative
explain how manage
discuss guidelines
solicit input
motivational strategy
professional liability

0,755
-0,174
0,781
0,715
0,839
0,791
0,642
0,726
0,681
0,431

Note: Decimals in this table are represented by commas, not periods.
Values > |0.40| are considered adequate loadings
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Table 4-p: Total Variance Explained EFA -3 (One-factor, 13-item)
Total Variance Explained
Initial Eigenvalues
Factor

Total

Sum of Squared loadings

%
%
variance cumulative

1

6,517

50,129

50,129

2
3

1,185
0,868

9,114
6,676

59,242
65,918

4
5
6
7
8
9
10
11
12
13

0,696
0,608
0,557
0,547
0,486
0,436
0,331
0,303
0,252
0,214

5,351
4,680
4,284
4,207
3,741
3,358
2,549
2,327
1,936
1,648

71,269
75,949
80,234
84,440
88,182
91,539
94,088
96,415
98,352
100,000

Total
6,052

%
%
variance cumulative
46,554

46,554

Note: Decimals in this table are represented by commas, not periods.

4.6 Factor Analysis – Round 4
One Factor Solution – 12 item scale
The fourth iterative round of EFA was a solution with a 12-item scale, excluding the item
described above in Round 3. All items loaded on the factor with values superior than 0.40.
(
Table 4-q). This 12-item solution explained 54% of the total variance (

Table 4-r). An illustration of the successive iterative rounds of EFA is presented on Figure
4-d.
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Given the clinical sense of this version and the high loadings resulting, the 12 items from
this 12-item one-factor solution were chosen to create the clinical inertia score as described
in Section 4.7 below.
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Figure 4-d: Illustration of the Iterative Process for EFA

EFA = Exploratory factor analysis

Table 4-q: Factor Matrix EFA – 4 (One-factor, 12-item)
Factor Matrix
Factor
1

effort track progress

0,682

advice increase monitor

0,565

prepared to help
time management
routine help
guideline informed
take initiative
explain how manage
discuss guidelines
solicit input
motivational strategy
professional liability

0,791
0,754
0,778
0,716
0,840
0,791
0,642
0,724
0,684
0,437

Note: Decimals in this table are represented by commas, not periods.
Values > |0.40| are considered adequate loadings
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Table 4-r: Total Variance Explained EFA – 4 (One-factor, 12-item)
Total Variance Explained

Factor
1

Initial Eigenvalues
%
%
Total
variance cumulative
6,484

54,034

54,034

2

1,007

8,394

62,428

3
4
5
6
7
8
9
10
11
12

0,697
0,634
0,569
0,551
0,489
0,437
0,331
0,324
0,256
0,220

5,805
5,284
4,741
4,593
4,074
3,646
2,762
2,701
2,130
1,837

68,233
73,516
78,257
82,850
86,924
90,570
93,332
96,033
98,163
100,000

Sum of Squared loadings
%
%
Total
variance cumulative
6,021

50,178

50,178

Note: Decimals in this table are represented by commas, not periods.

4.7 Clinical Inertia Score
A Clinical Inertia Score variable was created by calculating the mean of the response for
each of the 12 items for each respondent. Descriptive statistics and normality assessment
for this outcome variable are presented in Table 4-s and Figure 4-ef, respectively.
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Table 4-s: Descriptive Results
Clinical Inertia Score
N

Valid
Missing

Mean

2
3,8234

Median

3,8333

Standard Deviation
Percentile

160

0,61140

25

3,5000

50

3,8333

75

4,1667

Note: Decimals in this table are represented by commas, not periods. N= total number

Figure 4-e: Outcome normality assessment

4.8 The Relationship between the Clinical Inertia Score and
Family Physician Characteristics
A comparison of the outcome, the Clinical Inertia Score, to physician characteristics was
performed.
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Bivariate Analysis
Comparison of the continuous independent variables with the clinical inertia score
outcome, using Pearson’s correlations coefficient (Table 4-t), showed that none of the
comparisons achieved statistical significance.
An independent-samples t-test was conducted to compare the clinical inertia scores for each
group of respondents in the dichotomous variables of: sex (male/female), practice location
(rural/urban), country of medical degree (Canada/other countries), Diabetes Educator
designation (yes/no), personal diagnosis of DM (yes/no). None of the differences in scores
for these variables achieved statistical significance. Results are presented in Table 4-u.
Categorical variables with more than two response categories after recoding were analyzed
using one-way between groups ANOVA with post-hoc tests when appropriate. Mean,
minimum, maximum and standard deviation of scores for province and practice type
categories are presented on Table 4-v and Table 4-w respectively. There was no statistically
significant association between either province (Table 4-x) or type of practice (Table 4-y)
and clinical inertia score.

Table 4-t: Correlation for Continuous Variables and Clinical Inertia Score
Years in
# DM
score
Practice Age
pt/week
Pearson's r
1
0,093
0,066
0,059
Sig.
0,245
0,408
0,46
N
160
157
157
159
Note: Decimals in this table are represented by commas, not periods. DM = Diabetes; pt = patient; Sig. = Significance;
N=total number
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Table 4-u: Clinical Inertia Scores and T-test Results for Dichotomous variables
Average

12-item score

Sex

Male
Female
Practice
Urban
Location Rural
Country of Canada
Medical
Other
Degree
Country
Diabetes
Yes
Educator
No
Designation

Standard
Deviation Mínimum

Median

Maximum

3,90
3,72
3,82
3,84
3,81
3,87

0,56
0,66
0,62
0,59
0,60
0,66

2,42
1,58
1,58
2,42
1,58
2,42

4,00
3,83
3,83
3,83
3,83
4,00

5,00
5,00
5,00
4,83
5,00
5,00

3,97
3,81

0,48
0,62

3,42
1,58

3,75
3,83

4,75
5,00

Sig.
0,067
0,760

0,640

0,660

Note: Decimals in this table are represented by commas, not periods.

Table 4-v: Clinical Inertia Score for Province Categories
Province

Mean

Min

Max

Std Dev

ON
QU
NL
AB
Western/Prarie
Provinces
Maritimes
Provinces

3,792
3,847
3,889
3,958

1,583
2,417
2,833
2,750

5,000
4,833
4,750
5,000

0,646
0,645
0,522
0,769

3,975

3,333

5,000

0,468

3,618

2,667

4,167

0,457

Note: Decimals in this table are represented by commas, not periods. Min = Minimum; Max= Maximum; Std Dev =
Standard Deviation; ON = Ontario; QU = Quebec; NL = Newfoundland; AB = Alberta; WP = Western Prairies (British
Columbia, Manitoba and Saskatchewan); MP = Maritime Provinces (Prince Edward Island, New Brunswick and Nova
Scotia)
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Table 4-w: Clinical Inertia Score for Practice Type Categories
Type of Practice

Mean

Min

Max

Std Dev

Hospital
Team-based
Not Team-based
Missing

4,094
3,858
3,808
3,491

3,583
2,417
1,583
2,417

5,000
5,000
5,000
4,083

0,533
0,564
0,657
0,541

Note: Decimals in this table are represented by commas, not periods. Min = Minimum; Max = Maximum; Std Dev =
Standard Deviation

Table 4-x: ANOVA for Province Variable
Clinica Inertia Score

Between Groups
Within Groups
Total

Sum of
Squares

df

1,287
56,976
58,263

5
151
156

Mean
Square
0,257
0,377

Z

Sig.

0,682

0,638

Note: Decimals in this table are represented by commas, not periods. df = Degrees of freedom; Z = standard deviation;
Sig. = Significance

Table 4-y: ANOVA for Practice Type Variable
Clinica Inertia Score

Between Groups
Within Groups
Total

Sum of
Squares

df

1,672
52,507
54,18

3
143
146

Mean
Square
0,557
0,367

Z

Sig.

1,518

0,212

Note: Decimals in this table are represented by commas, not periods. df = Degrees of freedom; Z = standard deviation;
Sig. = Significance

Multiple Linear Regression
Multiple linear (MLR) regression was used to assess the ability of nine independent
variables (age in years, years in practice, average number DM patients per week, sex, urban
or rural practice location, province, personal diagnosis of DM, diabetes educator
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designation, practice type recoded) to predict the score on a Clinical Inertia Scale. This is
referred to as MLR-1.
Analyses were conducted on MLR-1 to ensure no violation of the assumptions of
normality, linearity, multicollinearity and homoscedasticity. Normal Probability (P-P) Plots
were inspected and the residuals rested well along the line indicating that both normality
and linearity assumptions were met for MLR-1.
Multicollinearity was verified by examination of the correlation matrix. The variable Age
was highly collinear with variable Years in Practice, with a bivariate correlation of 0.826,
with statistical significance (p value < 0.001).
Therefore, the independent variable Age was excluded from the regression and a second
multiple linear regression analysis (MLR -2) was performed. The correlation matrix for
MLR-2 is presented on Table 4-z. There was no evidence of multicollinearity for MLR-2.
The normal Probability (P-P) Plot was inspected and the residuals rested well along the line
indicating that both normality and linearity assumptions were met for MLR-2 (Figure 4-ff).
In the Scatterplot examination the standardised residuals for MLR -2 were distributed in a
rough rectangular shape, indicating that the assumption of homoscedasticity was met (
Figure 4-gg).
After examination of the relationships in MLR – 2, it was observed that none of the
variables were predictive of the Clinical Inertia Score. (
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Table 4-aa).

Table 4-z: Correlation in MLR -2
Pearson's
Correlation
Clinical Inertia Score
Years in Practice
# DM pt/week
Sex
Location
CDE
Personal diagnosis DM
Province (recoded)
Pratice Type (recoded)

1,000
0,093
0,059
-0,150
0,019
-0,060
-0,075
0,029
-0,151

Sig.

N

0,122
0,230
0,029
0,405
0,227
0,174
0,358
0,034

160
157
159
160
160
160
160
157
147

Note: Decimals in this table are represented by commas, not periods. Sig.= Significance; N = total number; DM =
Diabetes; pt = patient; CDE = Diabetes Educator designation
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Figure 4-f: P-P Plot MLR - 2

Note: Decimals in this graph are represented by commas, not periods.
Cum Prob = Cumulative Probability
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Figure 4-g: Scatterplot MLR -2
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Table 4-aa: Coefficients MLR – 2
Model

Unstandardized Coefficients
B

Std Error

(Constant)

4,324

0,67

Years in practice

0,002

0,005

# DM pt/week

0,001

Sex (Reference=Male)

Standardized
Coefficients

t

Confidence Interval for B
95,0%

Sig.

Beta

Lower Limit

Upper Limit

6,455

0

3

5,648

0,044

0,485

0,629

-0,008

0,012

0,002

0,029

0,321

0,749

-0,004

0,005

-0,179

0,115

-0,146

-1,559

0,121

-0,406

0,048

-0,014

0,127

-0,01

-0,112

0,911

-0,265

0,236

-0,009

0,24

-0,003

-0,036

0,971

-0,482

0,465

-0,18

0,184

-0,083

-0,977

0,33

-0,543

0,184

0,04

0,196

0,018

0,203

0,84

-0,347

0,426

Newfoundland

0,148

0,178

0,076

0,834

0,406

-0,203

0,499

Alberta

0,151

0,196

0,065

0,769

0,443

-0,237

0,538

Western provinces

0,217

0,175

0,109

1,241

0,217

-0,129

0,563

Maritime provinces

-0,206

0,201

-0,089

-1,024

0,307

-0,605

0,192

Family Health Team

0,013

0,146

0,01

0,089

0,929

-0,276

0,301

Other Practice Type

0,021

0,14

0,017

0,15

0,881

-0,256

0,298

Location
(Reference - Urban)
CDE
(Reference - Not a CDE)
Personal DM
(Reference - Do not
have DM)
Province
(Reference – Ontario)
Quebec

Practice Type
(Reference – Hospital)

Note: Decimals in this table are represented by commas, not periods.
Ref = Reference; Avg = average; CDE = Diabetes Educator Designation; DM = Diabetes Mellitus; WP = Western Prairies
(British Columbia, Manitoba and Saskatchewan); MP = Maritime Provinces (Prince Edward Island, New Brunswick and
Nova Scotia); Hosp = Hospital; FHT = Family Health Team.
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Chapter 5
Discussion
In this chapter, an overview of the findings is presented and is put into context by situating
it within the existing literature. The implications of these findings, and the strengths and
limitations of this study is also discussed. Finally, recommendations for future research
are highlighted.

5.1 Summary of Findings
The main contribution of this thesis to the literature is the creation, for the first time, of a
clinical inertia scale around hypoglycemia management. As a result of multiple iterations of
factor analysis, it is recommended that the scale be used in the form of a one 12-item scale.
While sub-scales were identified statistically, there was no conceptual distinction among
the sub-scales identified, and therefore it is not suggested that they be used without further
research. The results found in the standard multiple regression analysis showed that, for this
population, none of the differences in the clinical inertia score found in the family
physician characteristics variables achieved statistical significance. The characteristics
compared to the score were: age, sex, years in practice, average number of DM patients
seen per week, country of medical degree, practice type, practice location, DM educator
designation and personal diagnosis of diabetes.

5.2 Implication of Findings
A review of recent literature indicates that the management of hypoglycemia in primary
care setting by family physicians lacks thorough investigation. In fact, measuring clinical
inertia in family physicians’ management of hypoglycemia was an absent subject in the
extensive literature search that anticipated this research. The only available information
referred to research on similar topics, such as guideline adherence for the care of
hyperglycemia, clinical inertia related to other chronic problems and other general aspects
of DM management.
The major and novel contribution of this study to gain a better understanding of family
physician management of hypoglycemia, is the development of a practical measure for
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clinical inertia. The author believes that development of a clinical inertia score can be an
important and useful tool for family physicians and primary care services that wish to
improve the delivery of care to DM patients, specifically in the management of
hypoglycemia. It enables medical leaders, service managers and policy makers to assess
the measurement of clinical inertia in hypoglycemia management in physicians in primary
care. This in turn will enhance and increase awareness of this under-studied issue in family
medicine. Awareness may prompt discussions and reflection about hypoglycemia
management guidelines. This may, in turn, precipitate physician behavior modification
towards critically applying guideline recommendations to their practice and ultimately
improving outcomes for people with DM. The creation of a clinical inertia measure is a
novel contribution to the literature on hypoglycemia management that can guide future
research on the topic of physician behavior influencing management of hypoglycemia in
primary care settings.
At this point in the research, no reference values were identified for the scale. Higher
scores are intended to reflect less clinical inertia because higher scores reflect more positive
and proactive behaviors described in the items. Reference values concerning what
constitutes clinical inertia will be determined only after testing different populations of
family physicians and assessing the relationship between the scores and clinical
hypoglycemia on hypoglycemia management.
After creating the clinical inertia scale and calculating scores, this study examined potential
relationships between these scores and family physician characteristics that could be
associated with the phenomenon of clinical inertia in hypoglycemia management. Findings
from this analysis diverged from limited existing knowledge in three areas: sex, years of
practice and working in groups. Lang in 2015, affirmed that males were more prone to
clinical inertia49, and Sammer in 2008 stated that recent medical school graduates, women,
minorities, physicians who use computers for information in their practices, and physicians
in non-solo practice types were significantly less inclined to depart from guidelines.50 Yet,
this study found no difference in the clinical inertia score results between male or female
physicians. The existing literature also indicated that physicians with fewer years of
practice were more likely to follow guidelines50, but the results for the sample of family
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physicians in this study showed no tendency across years of practice. The same study by
Sammer in 2008 50 found that those physicians who worked in groups were more adherent
to guidelines, and therefore, less clinically inert. The analyses of the clinical inertia score
within the practice type variable (Hospital, Team-based or not team-based) did not find
such disparity in the current study.
No findings in this study corroborated with the limited existing knowledge on
hypoglycemia management in primary care that focus on the issue of clinical inertia. One
reason for this may be that the majority of the existing studies that examined physician
behavior towards clinical inertia in management of DM related problems, evaluated other
aspects of DM care, more consistent with hyperglycemia, such as failure to increase
pharmacologic treatment in the presence of off-target, elevated A1C hemoglobin.28, 48, 49
These fundamental differences in the objects of the cited studies and this research made it
difficult to compare results.
While this study would need to be replicated in larger and different populations, the new
evidence generated about clinical inertia around management of hypoglycemia suggests a
consistency in propensity to clinical inertia behavior across Canadian provinces or whether
the family physician worked in a rural or urban setting; inertia on the part of the physician
did not vary inversely to the volume of DM patients seen per week; a designation of DM
educator was not an advantage in preventing clinical inertia; and a personal diagnosis of
DM did not lessen nor encourage physician clinical inertia behavior in hypoglycemia
management. Given that some physician characteristics are not amenable to change, such as
age, sex, nationality of medical degree and personal diagnosis of diabetes, they do not
provide opportunities for interventions to change behaviour, and so would be of limited
practical value in tackling the problem of clinical inertia. Optimistically then, this may
suggest that other facets of care amenable to change, such as knowledge and support to
family physicians, may be the most strategic approach for interventions.
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5.3 Strengths and Limitations
The strength of this study is that it raises awareness and addresses an issue relevant to
primary care and family medicine world-wide, that of clinical inertia in hypoglycemia
management in primary care settings.
The preference for this statistical method, exploratory factor analysis, allowed for
observation of underlying constructs where no specific theory was available to explain the
phenomenon. This makes it an appropriate choice of statistical analysis for a primer study.
Data for the analysis were supplied by a major study designed and executed under a
rigorous scientific method. Respondents were from across Canada, representing a nationwide sample.
Recognizing possible limitations of this study is key to improving future research. One
limitation is that the survey used in this study was based on physicians’ self-report of their
behaviour and may not reflect actual behavior. Because of the secondary data analysis
nature of the study’s design, key aspects that could measure clinical inertia were not present
in the original questionnaire, such as attitudes and behavior of the physician in relation to
patient’s results on glycemic target or glycosylated hemoglobin levels; or questions about
the use of electronic medical records, telehealth and other technology-driven clinical
intelligence tools that could aid physicians in protocols and practice guidelines. Further
research could investigate and lead to expansion of the clinical inertia scale to include these
more behavioural components.
The original question about practice type (“Type of Practice: Hospital, Family Health
Team, Other: please specify_________”) was not precise enough to classify the team-based
characteristics of the physician’s practice. Re-classification was conducted to mitigate this
problem but the recoding criteria were not free from subjectivity. Practices considered as
“team based” for the purpose of re-classification were those entries that specifically
mentioned a team or multi-professional model of care, such as Primary Care Network,
Long-term and Palliative Care Institutions, Chronic Care Model. Entries considered as “not
team-based” were those that did not mention collaborative work with any other health
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professions such as solo or private practices, clinics comprised exclusively of physicians
and those that do not mention team work. However, a large number of entries were not
clear about the professional arrangement in the practice. In future research employing
physician surveys, a specific question about team-based practice, along with a clear
definition of what was being considered a team-based practice should be added to the
survey to improve the precision for measuring this construct, and perhaps improve the
prediction power of that item.
The item that was deleted for loading on a factor by itself, #14 of the InHypo-DM HCP
questionnaire, “addressing specific appointment issues take priority over discussing their
hypoglycemia management” refers to demands from the patient that compete for the
physician’s time and attention during a patient-physician encounter. This is a problem that
could explain in part the attitude of the physician for not acting when guidelines would
indicate an action is in order.51 So while the decision to delete this item from the current
clinical inertia scale was driven by statistic analysis, conceptually, the presence of
competing demands is an issue that should be explored in future research in order to better
understand its contribution to the phenomenon of physician clinical inertia in managing
hypoglycemia in primary care.
The interplay between patient and system factors influencing clinical inertia must not be
ignored. While this research was designed to understand the role of physician behaviors in
clinical inertia, future studies should also investigate physician clinical inertia behavior in
comparison to their patient’s characteristics, such as non-adherence status, A1C levels,
presence of comorbidity. The knowledge that will derive from such a comprehensive
understanding of the multi-factorial and complex topic of clinical inertia in primary care
will undoubtedly improve outcomes for DM patients.

5.4 Conclusion
This study is the first of its kind that explores a clinical inertia measurement for
hypoglycemia management in primary care and, as such, it serves as a primer, a basic
foundation for future research to test, validate and build upon. The creation of the clinical
inertia scale for hypoglycemia management is the first step in the development and
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validation of a scale to measure an important and largely under-studied clinical issue. It is
hoped that further validation of the scale will happen over time, as it is tested in other
family physician populations.
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Appendices
Appendix A: Recommendations from the 2018 CPG for Hypoglycemia in T2DM
Reference: Yale, JF et al. Diabetes Canada. 2018 Clinical Practice Guidelines,
Hypoglycemia. Can J Diabetes. 2018;42(Suppl 1): S1-S325.

1. All people with diabetes currently using or starting therapy with insulin or insulin
secretagogues and their support persons should be counselled about the risk,
prevention, recognition and treatment of hypoglycemia. Risk factors for severe
hypoglycemia should be identified and addressed [Grade D, Consensus].
2. The DHC team should review the person with diabetes' experience with
hypoglycemia at each visit, including an estimate of cause, frequency, symptoms,
recognition, severity and treatment, as well as the risk of driving with
hypoglycemia [Grade D, Consensus].
3. In people with diabetes at increased risk of hypoglycemia, the following strategies
may be used to reduce the risk of hypoglycemia:
a. Avoidance of pharmacotherapies associated with increased risk of recurrent or
severe hypoglycemia [Grade D, Consensus]
b. A standardized education program targeting rigorous avoidance of hypoglycemia
while maintaining overall glycemic control [Grade B, Level 2]
c. Increased frequency of SMBG, including periodic assessment during sleeping
hours [Grade D, Consensus]
d. Less stringent glycemic targets with avoidance of hypoglycemia for up to 3
months [Grade D, Level 4]
e. A psycho-behavioral intervention program (blood glucose awareness training)
[Grade C, Level 3]
f. Structured diabetes education and frequent follow up [Grade D, Consensus for
T2DM].
4. In people with diabetes with recurrent or severe hypoglycemia, or impaired
awareness of hypoglycemia, the following strategies may be considered to reduce
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or eliminate the risk of severe hypoglycemia and to attempt to regain
hypoglycemia awareness:
a. Less stringent glycemic targets with avoidance of hypoglycemia for up to 3
months [Grade D, Level 4]
5. Mild-to-moderate hypoglycemia should be treated by the oral ingestion of 15 g
carbohydrate, preferably as glucose or sucrose tablets or solution. These are
preferable to orange juice and glucose gels [Grade B, Level 2]. People with
diabetes should retest BG in 15 minutes and re-treat with another 15 g
carbohydrate if the BG level remains <4.0 mmol/L [Grade D, Consensus].
Note: This does not apply to children.
6. Severe hypoglycemia in a conscious person with diabetes should be treated by
oral ingestion of 20 g carbohydrate, preferably as glucose tablets or equivalent.
BG should be retested in 15 minutes and then re-treated with another 15 g glucose
if the BG level remains <4.0 mmol/L [Grade D, Consensus].
7. Severe hypoglycemia in an unconscious person with diabetes:
a. With no intravenous access: 1 mg glucagon should be given subcutaneously or
intramuscularly. Caregivers or support persons should call for emergency services
and the episode should be discussed with the DHC team as soon as possible
[Grade D, Consensus]
b. With intravenous access: 10–25 g (20–50 mL of D50W) of glucose should be
given intravenously over 1–3 minutes [Grade D, Consensus].
8. Once the hypoglycemia has been reversed, the person should have the usual meal
or snack that is due at that time of the day to prevent repeated hypoglycemia. If a
meal is >1 hour away, a snack (including 15 g carbohydrate and a protein source)
should be consumed [Grade D, Consensus].
9. For people with diabetes at risk of severe hypoglycemia, support persons should
be taught how to administer glucagon [Grade D, Consensus].
Abbreviations: A1C, glycated hemoglobin; BG, blood glucose; CVD, cardiovascular
disease; CGM, continuous glucose monitoring; CSII, continuous subcutaneous insulin
infusion; DHC, diabetes health-care team; SMBG, self-monitoring of blood glucose.
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Appendix B: InHypo-DM HealthCare Provider Questionnaire

Investigating Hypoglycemia: Your Perspectives on Diabetes Management Questionnaire
(InHYPO-DM_HCPQ)

Many people with diabetes experience hypoglycemia now and then. The following series of questions will
explore your thoughts, feelings, beliefs, and actions around helping your patients manage their hypoglycemia.
Please be as honest and accurate as possible. There are no correct answers. We are interested in your opinion.
There are 9 sections in total and other participants have taken 15 minutes to complete the survey. You may refuse
to answer any question you do not want to answer. All responses will be kept completely confidential.

PLEASE READ BEFORE STARTING:
Questions will apply to both the treatment and prevention of hypoglycemia. We will refer to this as hypoglycemia
management, unless specified. In addition, questions will refer to all “types” of hypoglycemia: mild or moderate
as well as severe hypoglycemia. Please refer to the definitions provided below, which describe each of these
“types” of hypoglycemia.
Mild or moderate hypoglycemia: When your patient has symptoms of hypoglycemia such as sweatiness, hunger,
anxiety, weakness, confusion, heart palpitations, difficulty speaking, and/or loses his/her train of thought but is
still able to take action to reverse these symptoms (for example by drinking a glass of juice, eating something,
or taking a sugar pill).
Severe hypoglycemia: When your patient absolutely needs assistance from someone else because he/she is either
unable to help him/herself or is not aware that he/she needs help.

SECTION 1

The following questions ask about your understanding of hypoglycemia and its
management. Remember that management refers to both treatment and prevention.
Please select the answer that you believe is true most of the time:
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SECTION 1 The following questions ask about your understanding of hypoglycemia and its management.
Remember that management refers to both treatment and prevention. Please select the answer that you
believe is true most of the time:

a) Please rate your level of knowledge:
Very low

Low

Moderate

High

Very high

1.) I would rate my level of knowledge about
hypoglycemia as:

○

○

○

○

○

2.) I would rate my level of knowledge about
hypoglycemia management as:

○

○

○

○

○

a) Please indicate your agreement with the following items:

In general…
3.) …I have enough knowledge to help my
patients manage their hypoglycemia.
4.) …I know where to go to find information
about managing hypoglycemia. Examples
may be printed materials (such as
guidelines), trusted websites, or
conferences.
5.) …I know where I can find support to help
my patients manage their hypoglycemia.
Examples may be consulting with another
healthcare provider or team member, or
referring a patient to another healthcare
provider, team member, or care centre.
6.) …I can access additional training or
learning programs if I want to in order to
help my patients manage their
hypoglycemia.

Strongly
disagree

Disagree

Neither
agree nor
Disagree

Agree

Strongly
agree

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○
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In general, I believe…
7.) …I have the skills to help my patients
manage their hypoglycemia.
8.) …I tailor the delivery of my
hypoglycemia care based on my
knowledge of my patients’ lifestyles and
contexts.
9.) …I am not as good as I could be at
helping my patients’ manage their
hypoglycemia.

SECTION 3

Strongly
disagree

Disagree

Neither
agree nor
Disagree

Agree

Strongly
agree

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

These are questions about what you actually do when helping your patients manage
their hypoglycemia. Remember that management refers to both treatment and
prevention. Please select the answer that you believe is true most of the time:
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In general…
10.) …I make an effort to keep track of my
patients’ progress with regard to
managing their hypoglycemia.
11.) …I advise my patients to increase the
frequency of blood glucose monitoring
when they are at increased risk for
hypoglycemia.
12.) …I make sure that I am prepared to help
my patients manage their hypoglycemia.
13.) …I am confident that I can help my
patients’ manage their hypoglycemia
even when there is little time.
14.) …addressing the specific appointment
issue takes priority over discussing their
hypoglycemia management.
15.) …helping my patients manage their
hypoglycemia is something I do
routinely.
16.) ...the way I help my patients manage their
hypoglycemia is informed by current
evidence and guidelines.
17.) …I take the initiative to help my patients
improve their hypoglycemia
management.
18.) …I explain how to manage hypoglycemia
to my patients.

Never

Rarely

Sometimes

Often

Always

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

19.) …I discuss hypoglycemia-related guidelines
regarding driving or operating heavy
machinery with my patients.

20.) …I solicit patients’ input when
discussing their hypoglycemia
management.
21.) …I use motivational strategies to help my
patients manage their hypoglycemia.
Examples may be praising, encouraging,
reminding, or warning.
22.) …my professional liability, according to my
specific regulatory body, directs the way I
manage patients’ hypoglycemia.

79

SECTION 4

The following questions ask about what supports you in helping your patients manage
their hypoglycemia. Remember that management refers to both treatment and
prevention. Please select the answer that you believe is true most of the time:

Strongly
disagree

Disagree

Neither
agree nor
Disagree

Agree

Strongly
agree

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

26.) …I know how to help motivate my
patients to manage their hypoglycemia.

○

○

○

○

○

27.) …I have clear goals for managing my
patients’ hypoglycemia.

○

○

○

○

○

○

○

○

○

○

In general…
23.) …I am committed to helping my patients
manage their hypoglycemia.
24.) …I know what helps me stay motivated
to help my patients’ care for their
hypoglycemia.
25.) …I believe that I have enough time to
help my patients manage their
hypoglycemia.

28.) …my goals regarding hypoglycemia
management align with my patients’
goals.
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SECTION 5

Healthcare providers may differ in their general outlook toward their management of
hypoglycemia. We are interested in how you view helping your patients manage their
hypoglycemia. Remember that management refers to both treatment and
prevention. Please select the answer that you believe is true most of the time:
Strongly
disagree

Disagree

Neither
agree nor
Disagree

Agree

Strongly
agree

○

○

○

○

○

30.) …it is my responsibility to society to help
my patients manage their hypoglycemia.

○

○

○

○

○

31.) …managing hypoglycemia is consistent
with my professional role.

○

○

○

○

○

32.) …I am optimistic about managing my
patients’ hypoglycemia in the future.

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

35.) …my patients’ health will benefit if I
help them manage their hypoglycemia.

○

○

○

○

○

36.) ...helping my patients manage their
hypoglycemia is challenging.

○

○

○

○

○

37.) …my patients adhere to my advice with
regard to hypoglycemia management.

○

○

○

○

○

○

○

○

○

○

In general, I believe that…
29.) …I share responsibility with my patients
for helping them manage their
hypoglycemia.

33.) …there is not much use in trying to help
my patients avoid hypoglycemia because
hypoglycemia will happen anyway.
34.) …the benefits of helping my patients
manage their hypoglycemia outweigh the
effort I put forth.

38.) …helping my patients’ manage their
hypoglycemia takes too much of my
energy.
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SECTION 6

Healthcare providers may have different ideas about what is and is not supportive
when it comes to helping their patients manage their hypoglycemia. Remember that
management refers to both treatment and prevention. We are interested in
whether your everyday professional life hinders or supports your ability to help your
patients manage their hypoglycemia. Please select the answer that you believe is true
most of the time:
Strongly
hinders

Hinders

Neither
hinders
nor
supports

Supports

Strongly
supports

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

In general, to what extent do/does…
39.) …your work environment affect your
ability to help your patients manage their
hypoglycemia?
Examples may be materials, staff support,
etc.
40.) …the resources provided to you affect
your ability to help your patients manage
their hypoglycemia?
Examples may be from local authorities,
employers, government, etc.
41.) …the media affect your ability to help
your patients manage their
hypoglycemia?
Examples may be the news, health
advertisements, professional networking
websites, publications, patient
posters/handouts, etc.
42.) …your professional role(s) affect your
ability to help your patients manage their
hypoglycemia?
43.) …your scope of practice affect your
ability to help your patients manage their
hypoglycemia.
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SECTION 7 We are also interested in how your social relationships affect your ability to help your
patients manage their hypoglycemia. Remember that management refers to both treatment and
prevention. Please select the answer that you believe is true most of the time:

In general, to what extent do/does your
relationship(s) with…
44.) …other healthcare providers with
whom you frequently work affect your
ability to help your patients manage their
hypoglycemia?
Examples may be physicians, nurses,
pharmacists, etc.
45.) …other healthcare providers in the
broader professional community affect
your ability to help your patients manage
their hypoglycemia?
Examples may be physicians, nurses,
pharmacists, etc.

Strongly
hinders

Hinders

Neither
hinders
nor
supports

Supports

Strongly
supports

○

○

○

○

○

○

○

○

○

○
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SECTION 8

Healthcare providers may experience worry and frustration regarding their patients’
risk and management of hypoglycemia. Remember that management refers to both
treatment and prevention. We are interested in knowing to what extent these
emotions affect how you help your patients manage their hypoglycemia. Please select
the answer that you believe is true most of the time:

a) Worry about your patients’ hypoglycemia risk and management:

46.) In general, how does worrying about
helping patients manage their
hypoglycemia affect your ability to do
so?

47.) Does this worry cause you to modify
recommended guidelines when helping
your patients manage their
hypoglycemia?

Strongly
hinders

Hinders

Neither
hinders
nor
Supports

Supports

Strongly
supports

○

○

○

○

○

Never

Rarely

Sometimes

Often

Always

○

○

○

○

○

a) Frustration about your patients’ hypoglycemia risk and management:

48.) In general, how does your frustration
about helping patients’ manage their
hypoglycemia affect your ability to do
so?

49.) Does this frustration cause you to modify
against recommended guidelines when
helping your patients manage their
hypoglycemia?

Strongly
hinders

Hinders

Neither
hinders
nor
Supports

Supports

Strongly
supports

○

○

○

○

○

Never

Rarely

Sometimes

Often

Always

○

○

○

○

○
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SECTION 9

This section contains questions related to your background and management of
patients’ mild/moderate or severe hypoglycemia events.

1. Sex:
Male
Female




2. Year of birth: _________
3. Location of practice:
Urban
Rural




4. Location of practice:
Province (pick from the list): (ON, QC, NS, NB, MB, BC, PE, SK, AB and NL)
5. Type of practice:
Hospital

Family Health Team

Other, please specify: ____________________________
6. What is your current profession?










Endocrinologist
Internal Medicine
Family Physician – Diabetes Specialist
Family physician
Nurse practitioner
Pharmacist
Nurse
Dietitian
Other ______________________

7. Are you a diabetes educator?
Yes
No




8. How long have you been practising in your current role (years)? ____________________________

9. Where did you obtain your most recent professional degree?
Type in name of country: ________________________________________
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1. How many people with diabetes do you see in an average week?
Type in the number of people: ____________
2. Of these people, approximately what proportion have been diagnosed with Type 1 diabetes
Type in the percentage of people: ____________ %
3. Of these people, approximately what proportion are taking medication for their diabetes that risks
hypoglycemia (for example insulin or sulyphonureas)?
Type in the percentage of people: ____________ %
4. Have you been diagnosed with diabetes?
Yes


If yes,

No

Type 1
Type 2






5. Have you ever experienced a diabetes-related hypoglycemia event?
Yes
No




6. Do you want to be entered in a drawing to win a prize?
Yes

→ Q 15.
No

→End of Survey
7.

If yes, please enter your email address below so that you can be included in a drawing for a prize.
This information will not be associated with your survey responses.
Email address
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